0001116463-25-000010 | 10-K | XBRL Viewer

Print Document

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail)	Dec. 31, 2024	Dec. 31, 2023
Lessee Disclosure [Abstract]
Weighted-average remaining lease term — operating leases	7 years 6 months 25 days	8 years 6 months 3 days
Weighted-average remaining lease term — finance leases	3 years 8 months 26 days	1 year 8 months 15 days
Weighted-average discount rate — operating leases	4.44%	3.71%
Weighted-average discount rate — finance leases	4.82%	3.45%

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current
Federal	$ 229	$ 0	$ 0
State	111	1,896	955
Foreign	2,116	605	2,154
Total current income tax expense (benefit)	2,456	2,501	3,109
Deferred
Federal	(2,962)	13,570	(2,250)
State	1,368	(382)	(633)
Foreign	4,365	(1,867)	(2,617)
Total deferred income tax expense (benefit)	2,771	11,321	(5,500)
Increase (decrease) in valuation allowance	(3,428)	(11,219)	3,849
Deferred income taxes	(657)	102	(1,651)
Total income tax expense	$ 1,799	$ 2,603	$ 1,458

Inventories - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory adjustments	$ 2.6	$ 8.9	$ 15.6

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
NET REVENUES:
Total revenue	$ 185,827	$ 405,472	$ 387,479
COST OF PRODUCTS AND SERVICES SOLD	106,437	233,820	239,041
Gross profit	79,390	171,652	148,438
OPERATING EXPENSES:
Research and development	26,047	33,728	36,237
Sales and marketing	30,986	36,319	49,238
General and administrative	46,215	58,191	68,206
Loss on impairments	4,392	10,829	17,101
Change in the estimated fair value of acquisition-related contingent consideration	0	(99)	(188)
Total operating expenses	107,640	138,968	170,594
Operating (loss) income	(28,250)	32,684	(22,156)
OTHER INCOME	12,249	23,574	6,481
(Loss) Income before income taxes	(16,001)	56,258	(15,675)
INCOME TAX EXPENSE	1,799	2,603	1,458
LOSS ON EQUITY INVESTMENT	(1,700)	0	0
NET (LOSS) INCOME	$ (19,500)	$ 53,655	$ (17,133)
(LOSS) INCOME PER SHARE:
Basic earnings per share (in US dollars per share)	$ (0.26)	$ 0.73	$ (0.24)
Diluted earnings per share (in US dollars per share)	$ (0.26)	$ 0.72	$ (0.24)
SHARES USED IN COMPUTING (LOSS) INCOME PER SHARE:
Basic weighted average number of shares outstanding (in shares)	74,434	73,348	72,505
Diluted weighted average number of shares outstanding (in shares)	74,434	74,389	72,505
Products and services
NET REVENUES:
Total revenue	$ 184,611	$ 402,222	$ 378,047
Other
NET REVENUES:
Total revenue	$ 1,216	$ 3,250	$ 9,432

Commitments and Contingencies

12 Months Ended

Dec. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

COMMITMENTS AND CONTINGENCIES:

Purchase Commitments

As of December 31, 2024, the Company had a manufacturing agreement with a third party vendor requiring a minimum purchase commitment. If the minimum commitment is not achieved, the Company will be required to make annual penalty payments over the next year. Based on current forecasts, these penalties aggregate to approximately $0.3 million and are accrued for in the consolidated balance sheet. These estimated penalties can fluctuate based on changes in forecasted demand.

The table below represents an estimate of future purchases under the agreement (in thousands):


2025	$	1,443
2026	—
2027	—
2028	—
2029	—
	$	1,443

Collaborations

Sherlock has an active third-party license agreement entered into in order to advance and obtain technologies and services related to the business. Under this license, the Company is required to make up to $2.3 million of cash payments upon the achievement of certain scientific and commercial milestones as well as low single digit royalty payments on product sales. No milestone payments have been made as of December 31, 2024. The Company has the right to terminate the license for any reason. Unless otherwise terminated, the license terminates upon the expiration of the last to expire valid claim.

Litigation

From time to time, the Company is involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected, individually or in the aggregate, to have a material adverse effect on the Company's future financial position or results of operations.

Spectrum Patent Litigation

In March 2021, the Company filed a complaint against Spectrum Solutions, LLC (“Spectrum”) in the United States District Court for the Southern District of California alleging that certain saliva collection devices manufactured and sold by Spectrum infringe a patent held by DNAG. Spectrum filed an answer asserting that its device does not infringe the Company’s patent and that the Company’s patent is invalid. In August 2021, the Company amended its complaint to add a second patent to this litigation. Spectrum responded to the Company's amended complaint and asserted counterclaims for inequitable conduct and antitrust violations with respect to one of the patents in the litigation and subsequently filed a request for review of the second patent at the Patent and Trademark Office (“PTO”), which was granted by the PTO. The District Court issued multiple pretrial orders, resolving the infringement, antitrust, and inequitable conduct claims without trial. First, the District Court granted Spectrum’s motion for summary judgment of noninfringement. Second, the Court denied Spectrum’s motion to supplement its allegations of alleged antitrust violations, finding that if such an amendment were allowed, Spectrum’s claims would not survive a motion for summary judgment. Spectrum thereafter withdrew its antitrust and inequitable conduct counterclaims. Spectrum did not appeal the District Court's denial of its motion to amend. The Company appealed the grant of summary judgment to the Court of Appeals on June 8, 2023. On February 14, 2025, the Court of Appeal affirmed the District Court’s judgment. The Company is considering its appellate options. On February 7, 2024, the PTO issued a Final Written Decision regarding the second patent in the litigation, holding that claims 1, 3–8, 11, and 12 of U.S. Patent No. 11,002,646 B2 are unpatentable. On March 8, 2024, the Company filed a Request for Rehearing by the Director of the PTO of the Final Written Decision. On March 27, 2024, the Company’s Request for Rehearing was denied. On September 15, 2023, Spectrum filed a separate petition for inter partes review of a third patent, which DNAG did not assert in the District Court. On March 26, 2024, the PTO issued a Decision Granting Institution of Inter Partes Review. On July 2, 2024, the Company filed a Motion to Amend the claims of the third patent and oral argument in this IPR took place on January 24, 2025. On February 19, 2025, the PTO issued a Final Written Decision regarding the third patent in the litigation, granting the Company's Motion to Amend as to cancelling the original claims,

but denying the Company's Motion to Amend as to adding proposed substitute claims. The Company is considering its appellate options.

NowDiagnostics Litigation

On November 14, 2024 the Company filed a complaint against NowDiagnostics, Inc. ("NowDx"), Jody Berry ("Berry") and Janean Young ("Young") in the United States District Court for the Eastern District of Pennsylvania alleging misappropriation and misuse of the Company's proprietary information and trade secrets by NowDx, Berry and Young in violation of the Federal Defend Trade Secrets Act and the Pennsylvania Uniform Trade Secrets Act. The complaint also alleges breach of contract and duty of loyalty by Young, unfair competition by NowDx, and tortious interference with contractual relations by Berry and NowDx. NowDx filed Counterclaims against the Company on January 13, 2025 and the Company filed its Answer to the Counterclaims on February 3, 2025. Young filed a Motion to Dismiss the claims against her, which was denied by the court on February 4, 2025. NowDx, Berry, and Young agreed to a preliminary injunction which the Court entered on February 27, 2025.

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Changes in goodwill are as follows:


	December 31,
Collection Device Reporting Unit	2024		2023
Balance as of January 1	$	35,696	$	35,104
Change related to foreign currency translation	(1,754)		592
Balance as of December 31	33,942		35,696

Diagnostics Reporting Unit
Balance as of January 1	—		—
Acquisition	6,388		—
Balance as of December 31	6,388		—
	$	40,330	$	35,696

Summary of Intangible Assets

Intangible assets consist of the following:


		December 31, 2024
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Definite Life Intangible Assets
Customer relationships	10	$	10,858	$	(10,858)	$	—
Patents and product rights	5	7,495		(7,399)		96
Developed technology	7-10	10,169		(10,169)		—
Trade names	5-15	4,327		(3,988)		339
		32,848		(32,413)		435
Indefinite Life Intangible Assets
IPR&D technology (Note 14)	N/A	17,000		—		17,000
		$	49,848	(32,413)		17,435


		December 31, 2023
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Definite Life Intangible Assets
Customer relationships	10	$	11,629	$	(11,629)	$	—
Patents and product rights	5	7,673		(7,102)		571
Developed technology	7-10	10,926		(10,926)		—
Trade names	5-15	4,626		(3,991)		635
		$	34,854	$	(33,649)	$	1,206

Summary of Amortization Expense

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2025	$	290
2026	145
2027	—
2028	—
2029	—
Beyond	—
	$	435

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

Business Combinations - Schedule of Purchase Price (Detail) - Sherlock Biosciences $ in Thousands	Dec. 19, 2024 USD ($)
Business Acquisition [Line Items]
Estimated fair value of contingent consideration	$ 22,910
Fair value of the royalty fee acquisition-related contingent consideration	7,000
Purchase price	5,000
Legal Fees	389
Insurance Policy Expense	50
Initial aggregate purchase price	28,349
Milestone Payments
Business Acquisition [Line Items]
Estimated fair value of contingent consideration	$ 15,910

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Unrecognized Tax Benefits [Roll Forward]
Balance at January 1	$ 304	$ 373	$ 805
Additions for tax positions of prior periods	29	0	1
Reductions for tax positions of prior periods	0	(69)	(433)
Balance at December 31	$ 333	$ 304	$ 373

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting [Abstract]
Net revenues	$ 185,827	$ 405,472	$ 387,479
COST OF PRODUCTS AND SERVICES SOLD	106,437	233,820	239,041
Gross profit	79,390	171,652	148,438
Research and development	26,047	33,728	36,237
Sales and marketing	30,986	36,319	49,238
General and administrative	46,215	58,191	68,206
Loss on impairments	4,392	10,829	17,101
Change in the estimated fair value of acquisition-related contingent consideration	0	(99)	(188)
Operating (loss) income	(28,250)	32,684	(22,156)
Other (expense) income (1)	(380)	17,836	3,453
Interest revenue	11,469	5,862	1,569
Other segment items (2)	1,160	(124)	1,459
(Loss) Income before income taxes	(16,001)	56,258	(15,675)
INCOME TAX EXPENSE	1,799	2,603	1,458
LOSS ON EQUITY INVESTMENT	(1,700)	0	0
NET (LOSS) INCOME	$ (19,500)	53,655	$ (17,133)
Revenue in excess of guaranteed profit		$ 12,800

Leases (Tables)

12 Months Ended

Dec. 31, 2024

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:


	For the Years Ended December 31,
	2024		2023		2022
Operating lease cost	$	1,729	$	2,407	$	2,910
Variable and short-term lease cost	549		381		521
Finance lease cost:
Amortization of right-of use assets	331		1,091		1,299
Interest on lease liabilities	22		51		94
Total finance lease cost	353		1,142		1,393
Total lease cost	$	2,631	$	3,930	$	4,824

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:


	For the Years Ended December 31,
	2024		2023		2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	1,901	$	1,863	$	2,209
Operating cash flows from financing leases	22		51		94
Financing cash flows from financing leases	842		1,345		1,381
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	4,086		4,363		3,963
Right-of-use assets obtained in exchange for finance lease obligations	193		334		117

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:


	December 31,
	2024		2023














Weighted Average Remaining Lease Term
Weighted-average remaining lease term — operating leases	7.57 years		8.51 years
Weighted-average remaining lease term — finance leases	3.74 years		1.71 years

Weighted Average Discount Rate
Weighted-average discount rate — operating leases	4.44	%	3.71	%
Weighted-average discount rate — finance leases	4.82	%	3.45	%

Schedule of Minimum Lease Payments by Period Expected

As of December 31, 2024, minimum lease payments by period are expected to be as follows:


	Finance		Operating
2025	$	48	$	2,559
2026	48		2,373
2027	42		2,141
2028	25		2,081
2029	6		2,020
Thereafter	—		5,722
Total minimum lease payments	169		16,896
Less: imputed interest	(15)		(2,446)
Present value of lease liabilities	$	154	$	14,450

Business Combinations - Additional Information (Detail) - USD ($)		12 Months Ended
	Dec. 19, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Net loss		$ (19,500,000)	$ 53,655,000	$ (17,133,000)
Sherlock Biosciences
Business Acquisition [Line Items]
Revenues		78,000.0
Net loss		255,400
Sherlock Biosciences
Business Acquisition [Line Items]
Contingent consideration, liability, value, high	$ 20,000,000.0
Estimated fair value of contingent consideration	22,910,000
Contingent consideration, liability, value, Low	0
Fair value of the royalty fee acquisition-related contingent consideration	7,000,000
Acquisition-related costs		$ 1,000,000.0
Sherlock Biosciences \| Milestone Payments
Business Acquisition [Line Items]
Estimated fair value of contingent consideration	$ 15,910,000

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Shares outstanding (in shares) \| shares	2,237
Weighted- Average Remaining Contractual Term (in years)	6 years 3 months 29 days
Weighted average exercise price (in US dollars per share)	$ 8.73
Shares exercisable (in shares) \| shares	1,389
Weighted average exercise price (in US dollars per share)	$ 9.79
Range One
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	4.26
Upper range limit (in US dollars per share)	$ 6.82
Shares outstanding (in shares) \| shares	578
Weighted- Average Remaining Contractual Term (in years)	7 years 4 months 6 days
Weighted average exercise price (in US dollars per share)	$ 5.98
Shares exercisable (in shares) \| shares	285
Weighted average exercise price (in US dollars per share)	$ 6.02
Range Two
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	7.13
Upper range limit (in US dollars per share)	$ 10.69
Shares outstanding (in shares) \| shares	1,277
Weighted- Average Remaining Contractual Term (in years)	6 years 6 months 3 days
Weighted average exercise price (in US dollars per share)	$ 7.89
Shares exercisable (in shares) \| shares	728
Weighted average exercise price (in US dollars per share)	$ 8.21
Range Three
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	12.90
Upper range limit (in US dollars per share)	$ 19.34
Shares outstanding (in shares) \| shares	334
Weighted- Average Remaining Contractual Term (in years)	4 years 3 months 29 days
Weighted average exercise price (in US dollars per share)	$ 14.87
Shares exercisable (in shares) \| shares	329
Weighted average exercise price (in US dollars per share)	$ 14.86
Range Four
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	21.64
Upper range limit (in US dollars per share)	$ 32.46
Shares outstanding (in shares) \| shares	48
Weighted- Average Remaining Contractual Term (in years)	2 years 9 months 10 days
Weighted average exercise price (in US dollars per share)	$ 21.65
Shares exercisable (in shares) \| shares	47
Weighted average exercise price (in US dollars per share)	$ 21.65

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Schedule of Estimate of Future Purchases

The table below represents an estimate of future purchases under the agreement (in thousands):


2025	$	1,443
2026	—
2027	—
2028	—
2029	—
	$	1,443

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2024

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities


	December 31,
	2024		2023
Payroll and related benefits	$	11,147	$	14,654
Professional fees	2,469		2,827
Sales tax payable	1,339		1,245
Other	5,224		3,984
	$	20,179	$	22,710

Leases

12 Months Ended

Dec. 31, 2024

Lessee Disclosure [Abstract]

Leases

LEASES:

The Company determines whether an arrangement is a lease at inception. The Company has operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of December 31, 2024, the Company is the lessee in all lease agreements. The Company's leases have remaining lease terms of one to ten years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within one year. The Company presents the operating right-of-use asset amortization and the change in operating lease liabilities on the other non-cash amortization line item of the consolidated statements of cash flows.

As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

The Company has lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, the Company accounts for lease components separately from non-lease components.

During the first quarter of 2024, the Company identified a triggering event to test for the recoverability of all the ROU assets of both the Diversigen and Novosanis subsidiaries, given the Company's decision to initiate a strategic plan to transition away from the microbiome molecular sequencing services business and close its Belgian operations. The Company performed an undiscounted cash flow analysis and determined the carrying values of the ROU assets could not be recovered through the sum of the undiscounted future cash flows and were impaired. During the year ended December 31, 2024 the Company recognized aggregate pre-tax impairment charges of $1.2 million and $0.3 million to its operating and finance ROU assets, respectively. These charges are reported in the Company's consolidated statement of operations.

The components of lease expense are as follows:


	For the Years Ended December 31,
	2024		2023		2022
Operating lease cost	$	1,729	$	2,407	$	2,910
Variable and short-term lease cost	549		381		521
Finance lease cost:
Amortization of right-of use assets	331		1,091		1,299
Interest on lease liabilities	22		51		94
Total finance lease cost	353		1,142		1,393
Total lease cost	$	2,631	$	3,930	$	4,824

Supplemental cash flow information related to leases is as follows:


	For the Years Ended December 31,
	2024		2023		2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	1,901	$	1,863	$	2,209
Operating cash flows from financing leases	22		51		94
Financing cash flows from financing leases	842		1,345		1,381
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	4,086		4,363		3,963
Right-of-use assets obtained in exchange for finance lease obligations	193		334		117

Supplemental balance sheet information related to leases is as follows:


	December 31,
	2024		2023














Weighted Average Remaining Lease Term
Weighted-average remaining lease term — operating leases	7.57 years		8.51 years
Weighted-average remaining lease term — finance leases	3.74 years		1.71 years

Weighted Average Discount Rate
Weighted-average discount rate — operating leases	4.44	%	3.71	%
Weighted-average discount rate — finance leases	4.82	%	3.45	%

As of December 31, 2024, minimum lease payments by period are expected to be as follows:


	Finance		Operating
2025	$	48	$	2,559
2026	48		2,373
2027	42		2,141
2028	25		2,081
2029	6		2,020
Thereafter	—		5,722
Total minimum lease payments	169		16,896
Less: imputed interest	(15)		(2,446)
Present value of lease liabilities	$	154	$	14,450

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 290
2026	145
2027	0
2028	0
2029	0
Beyond	0
Net	$ 435	$ 1,206

Commitments and Contingencies - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Estimated penalties to be incurred under minimum purchase commitments	$ 0.3
Contractual obligation	$ 2.3

Termination Benefits (Tables)

12 Months Ended

Dec. 31, 2024

Termination Benefits [Abstract]

Summary Of One-Time Termination Benefits

The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):


	For the Year Ended December 31,
	2023
Cost of products and services sold	$	369
Research and development	566
Sales and marketing	1,543
General and administrative	787
	$	3,265

The charges for termination benefits included in the Company's consolidated statement of operations are as follows (in thousands):


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	231
Research and development	87
Sales and marketing	69
General and administrative	17
	$	404

The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	889
Research and development	478
Sales and marketing	125
General and administrative	160
	$	1,652

The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	246
Research and development	33
Sales and marketing	782
General and administrative	141
	$	1,202

Business Combinations

12 Months Ended

Dec. 31, 2024

Business Combinations [Abstract]

Business Combinations

BUSINESS COMBINATIONS:

Sherlock Biosciences

On December 19, 2024, the Company acquired all of the outstanding stock of Sherlock, pursuant to the terms of a merger agreement (the "Merger Agreement"). The Company began operating this entity as of the December 19, 2024 closing date.

The primary reason for the acquisition is Sherlock's first test for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) is in clinical studies and is expected to be submitted to the FDA for approval by the end of 2025. Subject to regulatory approvals, this test is expected to expand the Company's portfolio for rapid diagnostics for sexually transmitted infections.

The initial aggregate purchase price of this transaction was funded with cash on had as shown below:


Milestone contingent consideration	$	15,910
Royalty based contingent consideration	7,000
Cash paid to Sherlock	5,000
Legal expenses	389
Insurance policy expense	50
Initial aggregate purchase price	$	28,349

Pursuant to the Merger Agreement, the Company agreed to pay up to $20.0 million of contingent consideration based on the achievement of a regulatory milestone on or before December 31, 2026 as defined in the Merger Agreement. The fair value of this milestone metric contingent consideration was $15.9 million. The range of outcome for the milestone contingent consideration is $0.0 million to $20.0 million. Also, there is a mid-single digits quarterly royalty fee based on future sales until 2034 as defined in the Merger Agreement, which was fair valued as part of contingent consideration. The estimated acquisition-date fair value of the royalty fee acquisition-related contingent consideration was $7.0 million. The range of outcome for the royalty payment cannot be determined due to the fact its based on future sales associated with the acquired in-process research and development technology through 2034 and thus does not have an upper limit.

During the year ended December 31, 2024, the Company incurred a total of $1.0 million of acquisition related costs, including accounting, legal, and other professional fees, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2024.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired


Other current assets	$	2,570
Property, plant, and equipment, net	9,244
Other noncurrent assets	462
Operating right-of-use assets	4,080
In-process research and development technology intangible asset	17,000
Goodwill	6,382
Total assets acquired	39,738
Liabilities Assumed
Accounts payable	2,449
Current liabilities	3,621
Deferred revenue	1,641
Operating lease liability	4,080
Total liabilities assumed	11,791
Net Assets Acquired	27,947
Estimated fair value of contingent consideration	(22,910)
Net Cash Paid (net of cash acquired of $402)	$	5,037

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets included in-process research and development technology ("IPR&D Technology"), which is an indefinite lived asset.

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets and contingent consideration of Sherlock. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The regulatory milestone scenario based model was used to value the assumed milestone contingent consideration, were primarily based on significant unobservable inputs and are considered Level 3 fair value measurements. The regulatory milestone scenario based model estimates fair value for contingent consideration based on the probability of on the achievement of a certain milestone as defined under the agreements and the discount rate.

The fair value of contingent payments approach was used to value the royalty based contingent consideration, were primarily based on significant unobservable inputs and are considered Level 3 fair value measurements. The fair value of contingent payments approach were primarily based on projected cash flows, probability of on the achievement of a regulatory milestone as defined under the agreements, and discount rate.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company believes the goodwill related to the acquisition was a result of Sherlock providing a product offering that will enable the Company to leverage those products with existing and new customers. The goodwill is not deductible for income tax purposes.

The Company continues to evaluate the fair value of certain assets acquired and liabilities assumed. Additional information, which existed as of the acquisition date, but was at that time unknown to the Company, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final determination may

result in a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition.

Revenues from Sherlock primarily consist of grant revenues for research and development purposes. Effective as of December 19, 2024, the financial results of Sherlock are included in the consolidated financial results of the Company. For the year ended December 31, 2024, consolidated net revenues include revenues associated with Sherlock of $78.0 thousand and consolidated results from operations include a net loss of $255.4 thousand generated since the acquisition date.

Unaudited Pro Forma Financial Information

The unaudited pro forma results presented below include the results of the Sherlock acquisition as if it had been consummated as of January 1, 2023. The unaudited pro forma results include, depreciation of the acquired property plant and equipment and the estimated tax effect of adjustments to income before income taxes but do not include changes in the fair value of the Company's contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2023.


	For the Years Ended December 31,
	2024		2023
Net revenues	$	188,126	$	406,381
Net income (loss)	$	(41,459)	$	7,992

Government Capital Contracts

12 Months Ended

Dec. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Government Capital Contracts

GOVERNMENT CAPITAL CONTRACTS:

In September 2021, the Company entered into an agreement for $109.0 million in funding from the U.S. Department of Defense (the "DOD"), in coordination with the Department of Health and Human Services, to build additional manufacturing capacity in the United States for its InteliSwab® COVID-19 Rapid Tests as part of the nation’s pandemic preparedness plan. In accordance with the milestone payment schedule, 15% of the total was not billed and funded until the completion of the final validation testing, which occurred in October 2023. The Company began receiving funds from the DOD in January 2022 and received $109.0 million as of December 31, 2023. In connection with the completion of the contract in the fourth quarter of 2023, all funds were received.

Activity for these capital contracts is accounted for pursuant to International Accounting Standards ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance. Funding received in relation to capital-related costs incurred for government contracts is recorded as a reduction to the cost of property, plant and equipment and reflected within investing activities in the consolidated statements of cash flows and associated unpaid liabilities and government proceeds receivable are considered non-cash changes in such balances within the operating section of the consolidated statements of cash flows.

Amounts earned for the Company's guaranteed profit which covered project management costs were recognized straight-line in other income over the term of the government contract. The Company recognized no such income during the year ended December 31, 2024. The Company recognized $2.8 million and $2.2 million of such income during the years ended December 31, 2023 and 2022, respectively. Additionally, in connection with the completion of the contract, the Company recognized $12.8 million in excess of the guaranteed profit in other income in the Company's consolidated statement of operations during the year ended December 31, 2023, which reflects the difference in overall spend compared to the firm fixed price contract amount of $109.0 million.

The DOD also reimbursed the Company for certain engineering consulting costs. These expenses are reflected in research and development expenses as incurred with the corresponding amount presented in other income. The Company

recognized no such costs during the year ended December 31, 2024. The Company recognized $2.0 million and $1.4 million of such costs during the years ended December 31, 2023 and 2022, respectively.

The activity corresponding to the government contracts included in the Company's consolidated statements of cash flows is as follows:


	December 31,
	2023
Cost of assets, cumulative	$	86,993
Reduction for funding earned to date, not yet received	—
Reduction for funding received to date	(86,993)
Total property, plant and equipment, net	$	—

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Income Tax Expense (Benefit)

Income (loss) before income tax expense consists of the following:


	For the Years Ended December 31,
	2024		2023		2022
United States	$	(21,523)	$	61,671	$	(7,111)
Foreign	5,522		(5,413)		(8,564)
	$	(16,001)	$	56,258	$	(15,675)

Components of Income Tax Expense (Benefit)

The components of income tax expense (benefit) are as follows:


	For the Years Ended December 31,
	2024		2023		2022
Current
Federal	$	229	$	—	$	—
State	111		1,896		955
Foreign	2,116		605		2,154
	2,456		2,501		3,109
Deferred
Federal	(2,962)		13,570		(2,250)
State	1,368		(382)		(633)
Foreign	4,365		(1,867)		(2,617)
	2,771		11,321		(5,500)
Increase (decrease) in valuation allowance	(3,428)		(11,219)		3,849
	(657)		102		(1,651)
Total income tax expense	$	1,799	$	2,603	$	1,458

Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate

The reconciliation of the statutory United States federal income tax rate to the Company's effective tax rate is as follows:


	For the Years Ended December 31,
	2024		2023		2022
Statutory U.S. federal income tax rate	21.0	%	21.0	%	21.0	%
Nondeductible executive compensation	(8.5)		0.5		(5.8)
Impact of stock-based payment awards	(2.3)		(0.3)		(5.1)
Tax effect of foreign items	(1.9)		(0.4)		(6.0)
State income taxes, net of federal benefit	(9.1)		2.0		(0.8)
U.S. and foreign tax credits	1.2		1.3		3.7

Nondeductible expenses and other	(2.4)		0.9		8.7

Nondeductible transaction costs	(2.1)		—		—
NOL adjustment, foreign	(31.4)		—		—
Non-controlling interests	2.2		—		—
Change in valuation allowance, federal and state	(10.0)		—		—
Change in valuation allowance, foreign	32.1		(20.4)		(25.0)
Effective tax rate	(11.2)	%	4.6	%	(9.3)	%

Components of Total Deferred Tax Assets (Liabilities)

Significant components of the Company's deferred tax assets (liabilities) are as follows:


	December 31,
	2024		2023
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	55,583	$	28,014
Inventories	2,344		2,654
Capitalized research and development costs	12,946		3,897
Accruals and reserves currently not deductible	2,754		3,324
Acquired intangible assets	(3,981)		(164)
Depreciation and amortization	(2,017)		(3,567)
Right-of-use assets	(2,266)		(3,010)
Lease liabilities	2,497		3,173
Stock-based compensation	3,303		3,467
Tax credit carryforwards	4,184		3,326
Net deferred tax asset	75,347		41,114
Valuation allowance	(75,191)		(41,668)
Net deferred tax asset (liability)	$	156	$	(554)

Summary of Operating Loss Carryforwards

The state NOL carryforwards have expirations as follows:


Year of Expiration	NOLs
2026 - 2040	$	14,122
2041 - 2046	13,442
Non-Expiring	10,294
	$	37,858

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

The reconciliation of the Company's unrecognized tax benefits is as follows:


	2024		2023		2022
Balance at January 1	$	304	$	373	$	805
Additions for tax positions of prior periods	29		—		1
Reductions for tax positions of prior periods	—		(69)		(433)
Balance at December 31	$	333	$	304	$	373

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNA Genotek, Inc. ("DNAG"), Diversigen, Inc. ("Diversigen"), Novosanis NV ("Novosanis"), and Sherlock Biosciences, Inc. ("Sherlock"). All intercompany transactions and balances have been eliminated. References herein to “we”, “us”, “our”, or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the fair value of assets acquired and liabilities assumed for business combinations, the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for property, plant and equipment, intangible assets and goodwill, as well as estimates related to accruals, taxes, contingent consideration, and performance-based compensation expense. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Supplemental Cash Flow Information

The Company paid income tax of $1.8 million in 2024, and received income tax refunds of $4.9 million in 2023 and paid income tax of $9.4 million in 2022.

The Company had account receivable write-offs of $0.5 million, $0.7 million, and $2.3 million in 2024, 2023, and 2022, respectively.

As of December 31, 2024, 2023 and 2022, the Company had accruals for purchases of property and equipment of $0.5 million, $0.2 million and $0.2 million, respectively.

The Company acquired Sherlock in exchange for contingent consideration of $22,910 for the year ended December 31, 2024.

Cash Equivalents & Short-Term Investments

The Company considers all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates purchased with maturities greater than ninety days. Securities with maturities ninety days or less are considered cash equivalents. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gain and losses, if any, reported in stockholders' equity as a component of other comprehensive loss.

The Company records an allowance for credit loss for the Company's available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, the Company reviews factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value, and the probability that the scheduled cash payments will continue to be made.

The Company had no available-for-sale securities as of December 31, 2024 and 2023.

The Company maintains cash balances in the United States in excess of the federally insured limits

Fair Value of Financial Instruments

As of December 31, 2024 and 2023, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

To the extent that valuation is based on models or inputs that are unobservable in the market, determining fair value requires more judgment. Because of the inherent uncertainty of valuation, estimated values may be materially higher or lower than the values that would have been used had a ready market for the investments existed. Therefore, the degree of judgment exercised in determining fair value is greatest for assets or liabilities categorized in Level 3.


		December 31,
	Level	2024		2023
Guaranteed investment certificates	1	$	66,584	$	71,698
Contingent consideration	3	$	22,910	$	—

Included in cash and cash equivalents at December 31, 2024 and 2023 was $66.6 million and $71.7 million, respectively, invested in guaranteed investment certificates.

Included in cash and cash equivalents at December 31, 2024 and 2023, was $118.5 million and $112.7 million, respectively, invested in government money market funds. These funds have investments in U.S. government securities and are measured as Level 1 instruments.

The Company offers a nonqualified deferred compensation plan for certain eligible employees and members of the Company's Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of December 31, 2024 and 2023 was $0.7 million and $0.8 million, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading

securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and other noncurrent assets with the same amounts included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.

Contingent Consideration

As further discussed in Note 14, Business Combinations, the Company has identified its contingent consideration obligations as Level 3 liabilities due to significant inputs that are required to measure the fair value of these obligations. The contingent consideration is comprised of two different tranches: milestone payments and royalty payments. The significant quantitative unobservable inputs for the milestone payments are the discount rate and probability achievement of a milestone of a regulatory approval.

The fair value methodology for royalty payments are based on a discounted cash flow model. Significant quantitative unobservable inputs are internally developed future expected cash flows, discount rate and probability achievement of a milestone of a regulatory approval. The royalty payments represent a mid-single digit percentage of the net sales through 2034 associated with the acquired in-process and research developed intangible asset.

There were no changes in fair value from date of acquisition to December 31, 2024.

Equity Method Investee

In January 2024, the Company lead the Series B financing and entered into wide-ranging strategic distribution agreements with KKR Sapphiros L.P. ("Sapphiros"), a privately held consumer diagnostic portfolio company, and certain of its related entities. Through this relationship, the Company expects to be able to offer a more comprehensive range of low-cost diagnostic tests and sample management solutions to the Company's customers globally. As of December 31, 2024, the Company had funded $30.0 million for its interest in Sapphiros. The Company recorded the investment using the equity method in accordance with Accounting Standards Codification ("ASC") Topic 323, Investments—Equity Method and Joint Ventures—Overall. In accordance with the equity method, the Company's equity investment is presented net of its share of any gains or losses of the investee. The Company has elected as its accounting policy to recognize its share of any income or loss in Sapphiros on a three-month lag, which coincides with the availability of its financial information. The investment in Sapphiros of $28.3 million as of December 31, 2024 is included in the investment in equity method investee line of the Company's balance sheet and is measured as a Level 3 investment. The Company has no unconditional obligations or guarantees to, or in support of, its equity method investee and its operations. In conjunction with the preparation of the Company's December 31, 2024 financial statements, the Company considered whether the carrying value of the investment in Sapphiros was impaired and concluded that no such impairment existed. There was no similar investment as of December 31, 2023.

Accounts Receivable

Accounts receivable has been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of the Company's customers and the Company's historical experience related to write-offs.


	December 31,
	2024		2023		2022
Accounts receivable	$	23,816	$	40,171	$	70,797
Allowance for doubtful accounts	$	774	$	1,216	$	2,365

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of the Company's inventories are subject to expiration dating, which can be extended in certain circumstances. The Company continually evaluates quantities on hand and the carrying value of the Company's inventories to determine the need for net realizable value adjustments for excess and obsolete inventories, based primarily on prior experience with consideration of expected changes in the business and estimated forecasts of product sales. The Company reserves for unidentified scrap or spoilage based on historical write-off rates. The Company also considers items identified through specific identification procedures in assessing the adequacy of the Company's reserve. Although the Company makes every effort to ensure the accuracy of expected changes in the business and of its forecasts of future product demand, any significant unanticipated changes in demand could have a significant impact on the carrying value of its inventories and reported operating results

Property, Plant and Equipment

Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets as follows:

•buildings twenty years;

•leasehold improvements, the lesser of the useful life of the improvement or the remaining life of the building or lease;

•computer equipment and software three years;

•machinery and equipment five years; and

•furniture and fixtures seven years

When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.

Intangible Assets

Intangible assets consist of customer relationships, patents and product rights, acquired technology, in-process research and development technology and trade names. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years.

Impairment of Long-Lived Assets

Long-lived assets, which include property, plant and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the Company's long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect the Company's assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time. See Notes 5 and 6 for discussion of property, plant and equipment and intangible asset impairments, respectively, recorded for the years ended December 31, 2024 and 2023.

Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Goodwill is not amortized but rather is tested annually for impairment or more frequently if the Company believes that indicators of impairment exist. Current generally accepted accounting principles permit the Company to make a qualitative evaluation about the likelihood of goodwill impairment. If the Company concludes that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then the Company would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The Company historically performed an annual goodwill impairment assessment as of July 31. During the three months ended December 31, 2023, the Company changed the date of its the annual impairment assessment to November 30, to better align with the Company's annual forecasting process. On November 30, 2024, the Company performed a quantitative goodwill impairment test which concluded that the carrying value of the Company's goodwill was below its fair value indicating there was no impairment.

A more frequent evaluation is performed if an event occurs or circumstances change between annual tests that could more likely than not reduce the fair value of a reporting unit below its carrying amount.

Revenue

Product sales. Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that reflects the consideration the Company is entitled to, net of allowances for any discounts or rebates.

The Company generally does not grant product return rights to its customers, except for warranty returns and return rights on sales of the Company's OraQuick® In-Home HIV test to retail trade customers, and InteliSwab® products to retail trade and certain other customers.

Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, the Company expenses warranty returns as incurred.

The Company records shipping and handling charges billed to the Company's customers as product revenue and the related expense as cost of products sold.

Service revenues. Service revenues represent microbiome laboratory testing and analytical services. The Company recognizes revenues when the Company satisfies its performance obligations for services rendered.

Arrangements with multiple-performance obligations. In arrangements involving more than one performance obligation, which largely applies to the Company's service revenue stream, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each performance obligation is determined using an observable cost plus margin approach. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services or when the performance obligation has been satisfied.

Other revenues. Other revenues consist primarily of royalty income and funding from grants of research and development efforts. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Research and development grant revenue is recognized pursuant to International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance ("IAS 20"). The expenses are recorded in research and development expense and the reimbursements are recorded in other revenue. Funding of research and development efforts and charitable support reimbursements are recorded as the activities are performed in accordance with the respective agreements.

Deferred revenue. The Company records deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2024 and 2023 included customer prepayments of $3.0 million and $1.2 million, respectively. Deferred revenue as of December 31, 2023 also included $0.4 million associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue was recognized at that average price. The $0.4 million associated with the long-term contract at December 31, 2023 met the criteria to be recognized as revenue during the year ended December 31, 2024, and as such there was no equivalent balance remaining in deferred revenue at December 31, 2024. Revenue recognized during the years ended December 31, 2024 and 2023 was $3.7 million and $2.6 million, respectively, which was included in the beginning period deferred revenue.


	December 31,
	2024		2023		2022
Deferred revenue	$	2,961	$	1,559	$	2,273

Financing and payment. The Company's payment terms vary by the type and location of the customer and products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and customer types, the Company may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Sales commissions are expensed when incurred if the amortization period is one year or less. These costs are recorded in sales and marketing expense in the consolidated statements of operations. If the amortization period exceeds one year, the Company defers the cost of the commission and expenses it over the life of the related sales contract.

Revenues by product. The following table represents total net revenues by product line:


	For the Years Ended December 31,
	2024		2023		2022
HIV	$	60,804	$	60,823	$	38,812
Sample Management Solutions (1)	51,046		54,274		63,342
COVID-19 (2)	45,172		257,779		243,325
HCV	14,024		12,871		13,369
Risk Assessment Testing (3)	8,354		9,736		10,269
Other product and services revenues (4)	3,506		2,265		1,634
Molecular Services	1,705		4,474		7,296
Net product and services revenues	184,611		402,222		378,047
Non-product and services revenues (5)	1,216		3,250		9,432
Net revenues	$	185,827	$	405,472	$	387,479

(1) Includes Genomics, Microbiome and Colli-Pee product revenues.

(2) Includes COVID-19 Diagnostics and COVID-19 Molecular Products revenues.

(3) Includes substance abuse testing product revenues.

(4) Includes Syphilis revenues.

(5) Includes funded research and development contracts, royalty income and grant revenues.

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	For the Years Ended December 31,
	2024		2023		2022
United States	$	139,161	$	361,660	$	350,206
Africa	32,745		29,254		18,152
Europe	8,424		8,111		11,536
Other regions	5,497		6,447		7,585
	$	185,827	$	405,472	$	387,479

Customer concentrations. The following table represents customer concentration risk:


	For the Years Ended December 31,
	2024	2023
Revenue Concentration

Non-commercial customer (1)	24%	63%

	December 31,
Accounts Receivable	2024	2023
Commercial customer	10%	N/A
Non-commercial customer (1)	N/A	40%

(1) Same non-commercial customer.

Vendor concentrations. The Company currently purchases certain products and critical components of the Company's products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, the Company could be subject to increased costs and substantial delays in the delivery of the Company's products to its customers. Third-party suppliers also manufacture certain products. The Company's inability to have a timely supply of any of these components and products could have a material adverse effect on the Company's business, as well as the Company's financial condition and results of operations.

Research and Development

Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2024, 2023, and 2022, the Company incurred $0.5 million, $1.6 million, and $4.8 million, respectively, in advertising expenses.

Stock-Based Compensation

The Company accounts for stock-based compensation to employees and directors using the fair value method. The Company recognizes compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. The Company recognizes compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate. To satisfy the exercise of stock options, issuance of restricted stock, or redemption of performance-based restricted stock units, the Company issues new shares rather than purchase shares in the open market.

Income Taxes

The Company follows the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company assesses the realizability of its net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, the Company reduces its net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the Company's net operating loss carryforwards.

Foreign Currency Translation

The assets and liabilities of the Company's foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in the Company's consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions included in other income in the Company's consolidated statements of operations were $1.2 million, $(0.1) million, and $1.6 million for the years ended December 31, 2024, 2023, and 2022, respectively.

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is anti-dilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price

during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.


	For the Years Ended December 31,
	2024		2023		2022
Net income (loss)	$	(19,500)	$	53,655	$	(17,133)
Weighted average shares of common stock outstanding:
Basic	74,434		73,348		72,505
Dilutive effect of stock options, restricted stock, and performance stock units	—		1,041		—
Diluted	74,434		74,389		72,505
Earnings per share:
Basic	$	(0.26)	$	0.73	$	(0.24)
Diluted	$	(0.26)	$	0.72	$	(0.24)

For the year ended December 31, 2024, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 896 shares were excluded from the computation of diluted loss per share. For the year ended December 31, 2023, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 1,778 shares were excluded from the computation of diluted earnings per share as their inclusion would have been antidilutive. For the year ended December 31, 2022, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 436 shares were excluded from the computation of diluted loss per share.

Accumulated Other Comprehensive Loss

The Company classifies items of other comprehensive income (loss) by their nature and discloses the accumulated balance of other comprehensive income (loss) separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of the Company's consolidated balance sheets.

The Company has defined the Canadian dollar as the functional currency of the Company's Canadian subsidiary, DNAG, and the Company has defined the Euro as the functional currency of the Company's Belgian subsidiary, Novosanis. The results of operations are translated into U.S. dollars, which is the reporting currency of the Company. Changes in accumulated other comprehensive loss by component is listed below:


	Foreign Currency		Total
Balance at December 31, 2023	$	(14,941)	$	(14,941)
Other comprehensive loss	(9,419)		(9,419)
Balance at December 31, 2024	$	(24,360)	$	(24,360)

Recent Accounting Pronouncements

In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses. The purpose of this update was to require disclosure, in the notes to financial statements, of specified information about certain costs and expenses on a disaggregated basis. The amendments in the ASU are effective for all public business entities for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The amendments are to be applied either prospectively to financial statements issued for reporting periods after the effective date of the update or retrospectively to any or all prior periods presented in the financial statements. Management is evaluating the impact on the Company's consolidated financial statements.

In March 2024, the FASB issued ASU No. 2024-01, Compensation—Stock Compensation (Topic 718), Scope Application of Profits Interest and Similar Awards. The purpose of this update was to provide illustrative examples to demonstrate how an entity should apply guidance to determine whether profits interests and similar awards should be accounted for in accordance with Topic 718. For public business entities, the amendments in this ASU are effective for fiscal years

beginning after December 15, 2024, and interim periods within those fiscal periods. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. Management is evaluating the impact on the Company's consolidated financial statements.

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures. The purpose of the update was to improve financial reporting by requiring disclosures of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this ASU are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and require retrospective application to all periods presented in the consolidated financial statements. The Company has adopted the amendments for the year ended December 31, 2024.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. The purpose of the update was to address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. The amendments in this ASU are effective for annual periods beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. Management is evaluating the impact on the Company's consolidated financial statements.

Immaterial Correction of Errors

In the first quarter of 2023, the Company identified an immaterial error that was corrected in its consolidated financial statements. Inventories, accounts payable and cost of products and services were reduced by $0.5 million, $1.3 million and $0.8 million, respectively, as of and for the year ended December 31, 2022 to correct for the accounting of a vendor rebate earned in 2022. Furthermore, stockholder's equity at December 31, 2022 increased $0.8 million to reflect the reduction in cost of products and services sold. The tax impact of the vendor rebate was negligible. This correction was deemed to be immaterial to the consolidated financial statements as of and for the year ended December 31, 2022. The respective operating activities on the consolidated statement of cash flows for the year ended December 31, 2022 have also been adjusted.

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income taxes paid	$ 1,800		$ 9,400
Proceeds from income tax refunds		$ 4,900
Write-offs against allowance for doubtful accounts	500	700	2,300
Accruals for purchases of property and equipment	500	200	200
Acquisition-related contingent consideration obligation	22,910	0
Cash and cash equivalents	267,763	290,407
Fair value of plan assets	700	800
Investment in unconsolidated entity	30,000	0	0
Investment in equity method investee	28,300	0
Deferred revenue, current	3,000	1,200
Deferred revenue, noncurrent		400
Deferred revenue, revenue recognized	3,700	2,600
Deferred revenue	$ 2,961	1,559	2,273
Sales commissions amortization period	1 year
Advertising expenses	$ 500	1,600	4,800
Net foreign exchange (losses) gains	1,200	(100)	1,600
Inventories	34,197	47,614
Accounts payable	8,173	13,151
Cost of products and services sold	106,437	233,820	239,041
Stockholders' equity	$ 410,338	430,671	364,425	$ 380,533
Buildings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years
Computer Equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	3 years
Machinery and equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	5 years
Furniture and fixtures
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	7 years
Revision of Prior Period, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories			(500)
Accounts payable			(1,300)
Cost of products and services sold			(800)
Stockholders' equity			$ 800
Level I Instruments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 66,584	71,698
Money Market Fund
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 118,500	$ 112,700
Common Stock Options Unvested Restricted Stock and Unvested Performance Units
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation (in shares)	896,000	1,778,000	436,000
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amortization Period (Years)	5 years
Contract with customer payment terms	30 days
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amortization Period (Years)	15 years
Contract with customer payment terms	120 days

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
United States	$ (21,523)	$ 61,671	$ (7,111)
Foreign	5,522	(5,413)	(8,564)
(Loss) Income before income taxes	$ (16,001)	$ 56,258	$ (15,675)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 111,023	$ 130,563
Accumulated depreciation	(65,918)	(85,143)
Total property, plant and equipment, net	45,105	45,420
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,118	1,118
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	36,152	34,606
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	51,015	64,156
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	11,502	17,739
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,621	3,748
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 9,615	$ 9,196

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2024

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

PROPERTY, PLANT AND EQUIPMENT:


	December 31,
	2024		2023
Land	$	1,118	$	1,118
Buildings and improvements	36,152		34,606
Machinery and equipment	51,015		64,156
Computer equipment and software	11,502		17,739
Furniture and fixtures	1,621		3,748
Construction in progress	9,615		9,196
	111,023		130,563
Accumulated depreciation	(65,918)		(85,143)
	$	45,105	$	45,420

During the first quarter of 2024, the Company initiated a strategic plan to transition away from the microbiome molecular sequencing services business and to cease operations at its Belgium location. As a result of these decisions, the Company determined that the carrying values of all of Diversigen's and Novosanis's property, plant, and equipment were not recoverable and recorded an aggregate pre-tax asset impairment charge of $1.8 million during the year ended December 31, 2024. All of these assets were disposed of as of December 31, 2024.

During the second quarter of 2024, the Company determined a manufacturing line will no longer be utilized. As a result of this decision, the Company determined that the carrying value of the equipment was not recoverable and recorded an aggregate pre-tax impairment charge of $1.1 million during the year ended December 31, 2024.

During the year ended December 31, 2023 the Company determined several manufacturing lines would not utilized due to changes in forecasted demand for the products the lines are intended to produce. Additionally, the Company elected not to proceed with certain leasehold improvements to its research and development laboratories. As a result of these decisions, the Company determined that the carrying values of the equipment and leasehold improvements were not recoverable and recorded aggregate pre-tax asset impairment charges of $2.3 million for the year ended December 31, 2023.

During the year ended December 31, 2022, the Company determined several manufacturing lines and associated supporting assets would not be utilized due to changes in forecasted demand for the products the lines are intended to produce. As a result of this decision, the Company determined that the carrying values of the equipment and supporting assets were not recoverable and recorded aggregate pre-tax asset impairment charges of $13.5 million for the year ended December 31, 2022. Due to the extremely specialized nature of the equipment and various market data points, the estimated fair value was zero. These charges are reported within loss on impairments in the consolidated statement of operations.

During the year ended December 31, 2023, the Company shortened the useful lives of machinery and equipment utilized for InteliSwab® production in Thailand. This reduction in useful lives resulted in $6.9 million of accelerated depreciation during 2023, recorded in cost of products and services sold. Also during 2023, the Company shortened the useful lives of leasehold improvements and equipment due a lease termination. This reduction in useful lives resulted in an additional $0.5 million of accelerated depreciation recorded in cost of products and services sold.

Depreciation expense for 2024, 2023, and 2022 was $9.8 million, $17.9 million, and $11.7 million, respectively.

Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Accounts receivable	$ 23,816	$ 40,171	$ 70,797
Allowance for doubtful accounts	$ 774	$ 1,216	$ 2,365

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 19, 2024	Dec. 31, 2023
Assets Acquired
Goodwill	$ 40,330		$ 35,696
Sherlock Biosciences
Assets Acquired
Other current assets		$ 2,570
Property, plant, and equipment, net		9,244
Other noncurrent assets		462
Operating right-of-use assets		4,080
In-process research and development technology intangible asset		17,000
Goodwill		6,382
Total assets acquired		39,738
Liabilities Assumed
Accounts payable		2,449
Current liabilities		3,621
Deferred revenue		1,641
Operating lease liability		4,080
Total liabilities assumed		11,791
Net Assets Acquired		27,947
Estimated fair value of contingent consideration		(22,910)
Net Cash Paid (net of cash acquired of $402)		5,037
Cash Acquired in Excess of Payments to Acquire Business		$ 402

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares) \| shares	2,070
Granted (in shares) \| shares	595
Exercised (in shares) \| shares	(32)
Expired (in shares) \| shares	(188)
Forfeited (in shares) \| shares	(208)
Ending balance (in shares) \| shares	2,237
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Vested or expected to vest (in shares) \| shares	2,198
Exercisable (in shares) \| shares	1,389
Beginning balance (in US dollars per share) \| $ / shares	$ 9.27
Granted (in US dollars per share) \| $ / shares	6.99
Exercised (in US dollars per share) \| $ / shares	6.70
Expired (in US dollars per share) \| $ / shares	11.19
Forfeited (in US dollars per share) \| $ / shares	7.20
Ending balance (in US dollars per share) \| $ / shares	8.73
Vested or expected to vest (in US dollars per share) \| $ / shares	8.72
Exercisable (in US dollars per share) \| $ / shares	$ 9.79
Weighted-average remaining contractual term, outstanding	6 years 3 months 29 days
Weighted-average remaining contractual term, vested or expected to vest	6 years 5 months 8 days
Weighted-average remaining contractual term, exercisable	4 years 10 months 28 days
Aggregate intrinsic value, outstanding \| $	$ 0
Aggregate intrinsic value, vested or expected to vest \| $	0
Aggregate intrinsic value, exercisable \| $	$ 0

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2024

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment


	December 31,
	2024		2023
Land	$	1,118	$	1,118
Buildings and improvements	36,152		34,606
Machinery and equipment	51,015		64,156
Computer equipment and software	11,502		17,739
Furniture and fixtures	1,621		3,748
Construction in progress	9,615		9,196
	111,023		130,563
Accumulated depreciation	(65,918)		(85,143)
	$	45,105	$	45,420

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lessee Disclosure [Abstract]
Operating lease cost	$ 1,729	$ 2,407	$ 2,910
Variable and short-term lease cost	549	381	521
Finance lease cost:
Amortization of right-of use assets	331	1,091	1,299
Interest on lease liabilities	22	51	94
Total finance lease cost	353	1,142	1,393
Total lease cost	$ 2,631	$ 3,930	$ 4,824

Consolidated Balance Sheets - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 267,763,000	$ 290,407,000
Accounts receivable, net of allowance for doubtful accounts of $774 and $1,216	23,816,000	40,171,000
Inventories	34,197,000	47,614,000
Prepaid expenses	3,956,000	6,041,000
Other current assets	3,488,000	2,226,000
Total current assets	333,220,000	386,459,000
Noncurrent Assets:
Property, plant and equipment, net of accumulated depreciation	45,105,000	45,420,000
Operating right-of-use assets, net	13,442,000	12,270,000
Finance right-of-use assets, net	145,000	576,000
Net	17,435,000	1,206,000
Goodwill	40,330,000	35,696,000
Investment in equity method investee	28,300,000	0
Deferred tax asset	156,000	0
Other noncurrent assets	1,526,000	1,218,000
Total noncurrent assets	146,439,000	96,386,000
TOTAL ASSETS	479,659,000	482,845,000
Current Liabilities:
Accounts payable	8,173,000	13,151,000
Deferred revenue	2,961,000	1,559,000
Accrued expenses and other current liabilities	20,179,000	22,710,000
Finance lease liability	41,000	539,000
Operating lease liability	2,129,000	1,577,000
Total current liabilities	33,483,000	39,536,000
Noncurrent Liabilities:
Finance lease liability	113,000	226,000
Operating lease liability	12,321,000	11,162,000
Acquisition-related contingent consideration obligation	22,910,000	0
Other noncurrent liabilities	494,000	696,000
Deferred income taxes	0	554,000
Total noncurrent liabilities	35,838,000	12,638,000
TOTAL LIABILITIES	69,321,000	52,174,000
Commitments and contingencies (Note 15)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued	0	0
Common stock, par value $.000001, 120,000 shares authorized, 74,598 and 73,528 shares issued and outstanding	0	0
Additional paid-in capital	538,129,000	529,543,000
Accumulated other comprehensive loss	(24,360,000)	(14,941,000)
Accumulated deficit	(103,431,000)	(83,931,000)
Total stockholders' equity	410,338,000	430,671,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 479,659,000	$ 482,845,000

Government Capital Contracts (Tables)

12 Months Ended

Dec. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Government Contracts Balances Included In Consolidated Statements Of Cashflows

The activity corresponding to the government contracts included in the Company's consolidated statements of cash flows is as follows:


	December 31,
	2023
Cost of assets, cumulative	$	86,993
Reduction for funding earned to date, not yet received	—
Reduction for funding received to date	(86,993)
Total property, plant and equipment, net	$	—

Stockholders' Equity

12 Months Ended

Dec. 31, 2024

Share-Based Payment Arrangement [Abstract]

Stockholders' Equity

STOCKHOLDERS’ EQUITY:

Stock-Based Awards

The Company grants stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards.

As of December 31, 2024, 5,412 shares were available for future grants under the Stock Plan.

Under the terms of the Stock Plan, nonqualified stock options may be granted to eligible employees, including the Company's officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of

grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	For the Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2024		2023		2022
Risk-free interest rate (1)	4.14	%	4.23	%	1.65	%
Expected dividend yield	—		—		—
Expected stock price volatility (2)	53	%	51	%	50	%
Expected life of stock options (in years) (2)	5		5		5

(1)Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options.

(2)Based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2024, 2023, and 2022 was $3.68, $3.24 and $4.15, respectively.

Compensation expense recognized in the financial statements related to stock options was $1.4 million, $1.3 million, and $1.5 million for the years ended December 31, 2024, 2023, and 2022, respectively.

The aggregate intrinsic value of options exercised during the years ended December 31, 2024, 2023, and 2022 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $38.4 thousand, $43.0 thousand, and $4.0 thousand, respectively.

The following table summarizes the stock option activity under the Stock Plan:


	Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding on January 1, 2024	2,070	$	9.27
Granted	595	6.99
Exercised	(32)	6.70
Expired	(188)	11.19
Forfeited	(208)	7.20
Outstanding on December 31, 2024	2,237	$	8.73	6.33	$	—
Vested or expected to vest as of December 31, 2024	2,198	$	8.72	6.44	$	—
Exercisable on December 31, 2024	1,389	$	9.79	4.91	$	—

As of December 31, 2024, there was $2.6 million of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.6 years.

Net cash proceeds from the exercise of stock options were $0.2 million, $0.3 million and $0.02 million for the years ended December 31, 2024, 2023, and 2022, respectively. As a result of the Company's net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding as of December 31, 2024:


Options Outstanding					Options Exercisable
Range of Exercise Prices	Number Outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price Per Share		Number Exercisable	Weighted- Average Exercise Price Per Share
$4.26 - $6.82	578	7.35	$	5.98	285	$	6.02
$7.13 - $10.69	1,277	6.51	7.89		728	8.21
$12.90 - $19.34	334	4.33	14.87		329	14.86
$21.64 - $32.46	48	2.78	$	21.65	47	$	21.65
	2,237	6.33	$	8.73	1,389	$	9.79

The Stock Plan also permits the Company to grant restricted shares and restricted units of the Company's common stock to eligible employees, including officers, and the Company's outside directors. Generally, these shares or units are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by the Company's Compensation Committee or Board of Directors. The market value of these shares and units at the date of grant is recognized on a straight-line basis over the period during which the vesting restrictions lapse. Compensation cost of $6.9 million, $7.6 million and $9.2 million related to restricted shares was recognized during the years ended December 31, 2024, 2023, and 2022, respectively.

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2024	2,521	$	6.04
Granted	875	6.84
Vested	(1,604)	5.81
Forfeited	(98)	7.37
Issued and unvested, December 31, 2024	1,694	$	6.60
Issued and expected to vest, December 31, 2024	1,694	$	6.60

As of December 31, 2024, there was $6.0 million of unrecognized compensation expense related to unvested restricted stock awards and unvested restricted stock units that is expected to be recognized over a weighted average period of 1.7 years.

In connection with the vesting of restricted shares during the years ended December 31, 2024, 2023, and 2022, the Company purchased and immediately retired 617, 262 and 241 shares with aggregate values of $3.4 million, $1.4 million and $1.6 million, respectively, in satisfaction of minimum tax withholding and exercise obligations.

The Company grants performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of certain performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in the Company's service for three years from the grant date. Performance shares were granted based on the achievement of three-year cumulative revenue metrics with a market-based condition, or a total shareholder return modifier. PSUs are converted into shares of the Company's common stock once vested and the number of shares actually earned at the end of the performance period will vary, based on actual performance, from 0% to 150% of the target number of performance share units granted. Upon grant of the PSUs, the Company recognizes compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate.

Compensation cost of $3.6 million, $1.8 million and $0.9 million related to the PSUs was recognized during the years ended December 31, 2024, 2023, and 2022, respectively.

The following table summarizes PSU activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2024	991	$	6.52
Granted (1)	519	8.87
Performance adjustment (2)	18	N/A
Vested	(74)	10.99
Forfeited	—	—
Issued and unvested, December 31, 2024	1,454	$	7.19
Issued and expected to vest, December 31, 2024	1,454	$	7.19

(1)Grant activity for all PSUs disclosed at target.

(2)Reflects the performance adjustment based on actual performance measured at the end of the performance period.

As of December 31, 2024, there was $5.3 million of unrecognized compensation expense related to unvested performance stock units that is expected to be recognized over a weighted average period of 1.7 years.

In connection with the vesting of performance stock units during the year ended December 31, 2024, 2023 and 2022, the Company purchased and immediately retired 23, 86, and 88 shares with aggregate values of $0.2 million, $0.5 million and $0.6 million, respectively.

Share Repurchase Program

On August 5, 2008, the Company's Board of Directors approved a share repurchase program pursuant to which the Company is permitted to acquire up to $25.0 million of the Company's outstanding common shares. No shares were purchased and retired during the years ended December 31, 2024, 2023, and 2022.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES:

Income (loss) before income tax expense consists of the following:


	For the Years Ended December 31,
	2024		2023		2022
United States	$	(21,523)	$	61,671	$	(7,111)
Foreign	5,522		(5,413)		(8,564)
	$	(16,001)	$	56,258	$	(15,675)

The components of income tax expense (benefit) are as follows:


	For the Years Ended December 31,
	2024		2023		2022
Current
Federal	$	229	$	—	$	—
State	111		1,896		955
Foreign	2,116		605		2,154
	2,456		2,501		3,109
Deferred
Federal	(2,962)		13,570		(2,250)
State	1,368		(382)		(633)
Foreign	4,365		(1,867)		(2,617)
	2,771		11,321		(5,500)
Increase (decrease) in valuation allowance	(3,428)		(11,219)		3,849
	(657)		102		(1,651)
Total income tax expense	$	1,799	$	2,603	$	1,458

For the years ended December 31, 2024, 2023, and 2022 the Company recorded net foreign income tax expense of $1.4 million, $0.7 million, and $0.5 million, respectively. The Company's 2022 foreign income tax expense included $1.7 million of Canadian withholding taxes paid on the repatriation of Canadian earnings offset by a foreign income tax benefit of $1.2 million associated with the Company's Canadian subsidiary. For the years ended December 31, 2024, 2023, and 2022 the Company recorded U.S. federal tax expense of $0.2 million and state tax expense of $0.1 million, $1.9 million, and $1.0 million respectively.

The reconciliation of the statutory United States federal income tax rate to the Company's effective tax rate is as follows:


	For the Years Ended December 31,
	2024		2023		2022
Statutory U.S. federal income tax rate	21.0	%	21.0	%	21.0	%
Nondeductible executive compensation	(8.5)		0.5		(5.8)
Impact of stock-based payment awards	(2.3)		(0.3)		(5.1)
Tax effect of foreign items	(1.9)		(0.4)		(6.0)
State income taxes, net of federal benefit	(9.1)		2.0		(0.8)
U.S. and foreign tax credits	1.2		1.3		3.7

Nondeductible expenses and other	(2.4)		0.9		8.7

Nondeductible transaction costs	(2.1)		—		—
NOL adjustment, foreign	(31.4)		—		—
Non-controlling interests	2.2		—		—
Change in valuation allowance, federal and state	(10.0)		—		—
Change in valuation allowance, foreign	32.1		(20.4)		(25.0)
Effective tax rate	(11.2)	%	4.6	%	(9.3)	%

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of the Company's deferred tax assets (liabilities) are as follows:


	December 31,
	2024		2023
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	55,583	$	28,014
Inventories	2,344		2,654
Capitalized research and development costs	12,946		3,897
Accruals and reserves currently not deductible	2,754		3,324
Acquired intangible assets	(3,981)		(164)
Depreciation and amortization	(2,017)		(3,567)
Right-of-use assets	(2,266)		(3,010)
Lease liabilities	2,497		3,173
Stock-based compensation	3,303		3,467
Tax credit carryforwards	4,184		3,326
Net deferred tax asset	75,347		41,114
Valuation allowance	(75,191)		(41,668)
Net deferred tax asset (liability)	$	156	$	(554)

In assessing the realizability of the Company's deferred tax asset, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income, to realize the NOL carryforwards. In 2008, the Company established a full valuation allowance against the Company's U.S. deferred tax asset, and although the Company has achieved cumulative of U.S. pre-tax earnings based on a rolling three year window the Company has not achieved a level of sustained profitability that would, in the Company's judgement, support the release of the valuation allowance. Management believes the full valuation allowance is still appropriate as of December 31, 2024 and 2023. As a result, no U.S. federal income tax benefit was recorded for the years ended December 31, 2024, 2023, and 2022.

The Company's federal NOL carryforwards consist of $108.6 million from existing business along with $71.5 million of acquired NOL carryforwards. None of these NOL carryforwards have an expiration date. The Company's foreign NOL carryforwards consist of $63.0 million of acquired NOL carryforwards. These foreign NOL carryforwards do not have an expiration date. The Company's state NOL carryforwards consist of $33.9 million from existing business along with $4.0 million of acquired NOL carryforwards. The state NOL carryforwards have expirations as follows:


Year of Expiration	NOLs
2026 - 2040	$	14,122
2041 - 2046	13,442
Non-Expiring	10,294
	$	37,858

The Tax Reform Act of 1986 contains provisions under Internal Revenue Code (“IRC”) Section 382 that limit the annual amount of federal and state NOL carryforwards that can be used in any given year in the event a significant change in ownership. The Company does not believe that there is a Section 382 limitation that will impair the Company's future ability to utilize NOLs to offset the Company's future taxable income. The Company continues to review ownership changes on an annual basis and the Company does not believe it has had a subsequent ownership change that would impact the NOLs. The Company acquired 382 limited NOL carryforwards as part of its acquisition of Sherlock. These NOL carryforwards have no expiration date.

In January 2022, approximately $65.0 million was repatriated from the Company's Canadian subsidiary as a one-time event. Associated with this repatriation the Company paid $1.7 million in Canadian withholding tax which is included in the Company's foreign income tax expense within the table further above. It is still the Company's intention to continue to permanently reinvest the historical undistributed earnings of the Company's foreign subsidiary to the extent that the Company will not incur any additional tax expense associated with foreign withholding or other local tax expense on the future cash transfers. As such, deferred taxes have not been recorded on the unremitted earnings of the foreign subsidiary as of December 31, 2024.

As of December 31, 2024, the Company's gross unrecognized tax benefits totaled $0.3 million, and based upon the valuation allowance for the Company's U.S. operations, the recognition of any tax benefit would not impact the Company's effective tax rate. The Company records interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2024, 2023, and 2022. As a result of the Company's NOL carryforward position, the Company has been subject to audit by the Internal Revenue Service since the Company's inception, as well as by several jurisdictions for the years ended September 30, 1998 through December 31, 2024.

The reconciliation of the Company's unrecognized tax benefits is as follows:


	2024		2023		2022
Balance at January 1	$	304	$	373	$	805
Additions for tax positions of prior periods	29		—		1
Reductions for tax positions of prior periods	—		(69)		(433)
Balance at December 31	$	333	$	304	$	373

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation Of Revenue [Line Items]
Net revenues	$ 185,827	$ 405,472	$ 387,479
Product and Services Revenues
Disaggregation Of Revenue [Line Items]
Net revenues	184,611	402,222	378,047
Product and Services Revenues \| HIV
Disaggregation Of Revenue [Line Items]
Net revenues	60,804	60,823	38,812
Product and Services Revenues \| Sample Management Solutions
Disaggregation Of Revenue [Line Items]
Net revenues	51,046	54,274	63,342
Product and Services Revenues \| COVID-19
Disaggregation Of Revenue [Line Items]
Net revenues	45,172	257,779	243,325
Product and Services Revenues \| HCV
Disaggregation Of Revenue [Line Items]
Net revenues	14,024	12,871	13,369
Product and Services Revenues \| Risk Assessment Testing
Disaggregation Of Revenue [Line Items]
Net revenues	8,354	9,736	10,269
Product and Services Revenues \| Other Product And Services Revenues
Disaggregation Of Revenue [Line Items]
Net revenues	3,506	2,265	1,634
Product and Services Revenues \| Molecular Services
Disaggregation Of Revenue [Line Items]
Net revenues	1,705	4,474	7,296
Other
Disaggregation Of Revenue [Line Items]
Net revenues	185,827	405,472	387,479
Other \| Non-product and services revenues
Disaggregation Of Revenue [Line Items]
Net revenues	$ 1,216	$ 3,250	$ 9,432

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Use of Estimates

Supplemental Cash Flow Information

The Company paid income tax of $1.8 million in 2024, and received income tax refunds of $4.9 million in 2023 and paid income tax of $9.4 million in 2022.

The Company had account receivable write-offs of $0.5 million, $0.7 million, and $2.3 million in 2024, 2023, and 2022, respectively.

As of December 31, 2024, 2023 and 2022, the Company had accruals for purchases of property and equipment of $0.5 million, $0.2 million and $0.2 million, respectively.

The Company acquired Sherlock in exchange for contingent consideration of $22,910 for the year ended December 31, 2024.

Cash Equivalents & Short-Term Investments

The Company had no available-for-sale securities as of December 31, 2024 and 2023.

The Company maintains cash balances in the United States in excess of the federally insured limits

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).


		December 31,
	Level	2024		2023
Guaranteed investment certificates	1	$	66,584	$	71,698
Contingent consideration	3	$	22,910	$	—

Included in cash and cash equivalents at December 31, 2024 and 2023 was $66.6 million and $71.7 million, respectively, invested in guaranteed investment certificates.

Contingent Consideration

There were no changes in fair value from date of acquisition to December 31, 2024.

Equity Method Investee

Accounts Receivable

Inventories

Property, Plant and Equipment

•buildings twenty years;

•leasehold improvements, the lesser of the useful life of the improvement or the remaining life of the building or lease;

•computer equipment and software three years;

•machinery and equipment five years; and

•furniture and fixtures seven years

When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.

Intangible Assets

Impairment of Long-Lived Assets

Goodwill

Revenues

Revenue

Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, the Company expenses warranty returns as incurred.

The Company records shipping and handling charges billed to the Company's customers as product revenue and the related expense as cost of products sold.


	December 31,
	2024		2023		2022
Deferred revenue	$	2,961	$	1,559	$	2,273

For certain products or services and customer types, the Company may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Vendor Concentrations

Research and Development

Advertising Expenses

Advertising costs are charged to expense as incurred.

Stock-Based Compensation

Income Taxes

Foreign Currency Translation

Earnings (Loss) Per Share

during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.


	For the Years Ended December 31,
	2024		2023		2022
Net income (loss)	$	(19,500)	$	53,655	$	(17,133)
Weighted average shares of common stock outstanding:
Basic	74,434		73,348		72,505
Dilutive effect of stock options, restricted stock, and performance stock units	—		1,041		—
Diluted	74,434		74,389		72,505
Earnings per share:
Basic	$	(0.26)	$	0.73	$	(0.24)
Diluted	$	(0.26)	$	0.72	$	(0.24)

Accumulated Other Comprehensive Loss

Recent Accounting Pronouncements

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 1,901	$ 1,863	$ 2,209
Operating cash flows from financing leases	22	51	94
Financing cash flows from financing leases	842	1,345	1,381
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	4,086	4,363	3,963
Right-of-use assets obtained in exchange for finance lease obligations	$ 193	$ 334	$ 117

Transition Costs	12 Months Ended
Transition Costs	Dec. 31, 2024
Transition Costs [Abstract]
Transition Costs	TRANSITION COSTS On December 31, 2021, the Company's Board of Directors approved the termination of Stephen S. Tang, the Company’s President and Chief Executive Officer, without cause under his existing employment agreement with the Company, with such termination effective as of March 31, 2022. On January 2, 2022, Dr. Tang and the Company entered into a Transition Agreement providing for the terms of the cessation of Dr. Tang’s employment with the Company, including the cessation of his service as President and Chief Executive Officer of the Company and as a member of the Board. Under the Transition Agreement, Dr. Tang’s service to the Company in all capacities ended on March 31, 2022. Pursuant to the Transition Agreement, Dr. Tang received severance of $1.6 million, which was accrued in the consolidated financial statements at December 31, 2021 and paid in April 2022. Additionally, in accordance with his Transition Agreement, certain of his unvested time-vesting restricted stock awards and unvested PSUs that were outstanding at March 31, 2022 vested on April 8, 2022. His remaining unvested time-vesting restricted stock awards and PSUs were forfeited on March 31, 2022. These payments, rights and benefits are substantially similar to the severance benefits contemplated by his previous employment agreement in respect to a termination without cause thereunder. In aggregate, the Company recognized $1.5 million of expense in relation to Dr. Tang's stock compensation for the year ended December 31, 2022.

Business Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table represents reported segment revenues, segment profit (loss), and significant segment expenses:


	For the Years Ended December 31,
	2024		2023		2022
Net revenues	$	185,827	$	405,472	387,479
Cost of products and services sold (3)	106,437		233,820		239,041
Gross profit	79,390		171,652		148,438
Research and development (3)	26,047		33,728		36,237
Sales and marketing (3)	30,986		36,319		49,238
General and administrative (3)	46,215		58,191		68,206
Loss on impairments	4,392		10,829		17,101
Change in the estimated fair value of acquisition-related contingent consideration	—		(99)		(188)
Operating (loss) income	(28,250)		32,684		(22,156)
Other (expense) income (1)	(380)		17,836		3,453
Interest revenue	11,469		5,862		1,569
Other segment items (2)	1,160		(124)		1,459
(Loss) income before income taxes	(16,001)		56,258		(15,675)
Income tax expense	1,799		2,603		1,458
Loss on equity investment	(1,700)		—		—
Net (loss) income	$	(19,500)	$	53,655	$	(17,133)

(1) Includes $12.8 million of excess profits recognized on government contracts in 2023.

(2) Includes interest expense and foreign currency gains (losses).

(3) The following tables represent additional significant segment expense categories:


	For the Years Ended December 31,
	2024		2023		2022
Stock-based Compensation
Cost of products and services sold	$	734	$	564	$	334
Research and development	839		1,159		1,128
Sales and marketing	1,129		1,181		1,702
General and administrative	9,219		7,826		8,458
	$	11,920	$	10,729	$	11,622


	For the Years Ended December 31,
	2024		2023		2022
Depreciation and Amortization
Cost of products and services sold	$	6,343	$	15,311	$	9,230
Research and development	1,029		1,208		1,098
Sales and marketing	189		571		630
General and administrative	3,311		3,846		4,350
	$	10,872	$	20,936	$	15,308

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

GOODWILL AND OTHER INTANGIBLE ASSETS:

Changes in goodwill are as follows:


	December 31,
Collection Device Reporting Unit	2024		2023
Balance as of January 1	$	35,696	$	35,104
Change related to foreign currency translation	(1,754)		592
Balance as of December 31	33,942		35,696

Diagnostics Reporting Unit
Balance as of January 1	—		—
Acquisition	6,388		—
Balance as of December 31	6,388		—
	$	40,330	$	35,696

On November 30, 2024, the Company performed its quantitative annual goodwill impairment test. The Company utilizes a combination of the income approach and market approach in determining the fair value of its two reporting units. The test concluded that the carrying value of the Company's reporting units was below fair value indicating there was no impairment of goodwill.

During 2022, the Company determined that a triggering event occurred in relation to the depressed market price of the Company's common stock and corresponding decline in the Company's market capitalization. As a result, the Company performed an interim quantitative goodwill impairment test and concluded that the carrying value of the Company's Diagnostics reporting unit exceeded its estimated fair value and the goodwill balance for that segment was fully impaired. The Company recognized a pre-tax impairment charge of $3.6 million during the year ended December 31, 2022, which is reported in loss on impairments in the Company's consolidated statement of operations.

Intangible assets consist of the following:


		December 31, 2024
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Definite Life Intangible Assets
Customer relationships	10	$	10,858	$	(10,858)	$	—
Patents and product rights	5	7,495		(7,399)		96
Developed technology	7-10	10,169		(10,169)		—
Trade names	5-15	4,327		(3,988)		339
		32,848		(32,413)		435
Indefinite Life Intangible Assets
IPR&D technology (Note 14)	N/A	17,000		—		17,000
		$	49,848	(32,413)		17,435


		December 31, 2023
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Definite Life Intangible Assets
Customer relationships	10	$	11,629	$	(11,629)	$	—
Patents and product rights	5	7,673		(7,102)		571
Developed technology	7-10	10,926		(10,926)		—
Trade names	5-15	4,626		(3,991)		635
		$	34,854	$	(33,649)	$	1,206

During 2023, the Company identified a triggering event to test for the recoverability of intangible assets given the decline in the Company's market capitalization leading up to and as of its annual goodwill impairment testing date. The Company performed an undiscounted cash flow analysis and determined the carrying value of the developed technology, trade names, and customer relationships intangible assets could not be recovered through the sum of the undiscounted future cash flows. The Company used an income approach to determine the fair value of the developed technology and customer relationships intangible assets and the relief from royalty method for the trade names. As a result of this analysis, the Company determined the intangible assets associated with Diversigen and Novosanis were impaired as the fair value of the developed technology, trade names, and customer relationships did not exceed their carrying value. The Company recognized a pre-tax impairment charge of $6.2 million during the year ended December 31, 2023 which is reported in loss on impairments in the Company's consolidated statement of operations.

Also in 2023, the Company determined that its remaining developed technology intangible asset was fully impaired. As a result of failed stability studies, the Company decided to no longer pursue the technology. The Company recognized a pre-tax impairment charge of $2.4 million during the year ended December 31, 2023 which is reported in loss on impairments in the Company's consolidated statement of operations.

Amortization expense for 2024, 2023, and 2022 was $0.7 million, $2.0 million, and $2.3 million, respectively.

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2025	$	290
2026	145
2027	—
2028	—
2029	—
Beyond	—
	$	435

The Company	12 Months Ended
The Company	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	THE COMPANY: OraSure Technologies transforms health through actionable insight by powering the shift that connects people to healthcare wherever they are. In February 2023, the Company announced a corporate restructuring to combine the commercial and innovation teams across two segments, being the “Diagnostics” segment and the “Molecular Solutions” segment, into one business unit with sales, marketing, product development, and research teams covering multiple product lines. This change is intended to accelerate innovation, enhance customer experience and result in operational synergies. As a result, all products and services reside under one reporting hierarchy. The Company's product portfolio is broadly divided into diagnostics products and sample management solutions. The Company's business consists of the development, manufacture, marketing and sale of simple, easy to use specimen collection devices and diagnostic products designed to detect certain infectious diseases including COVID-19, HIV and Hepatitis C, and Syphilis that are performed on a rapid basis at the point of care. The Company's business also includes sample management solutions and molecular services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers. During 2024, the Company exited the molecular services business. In October 2024, the Company announced the discontinuance of the sales of its risk assessment product line which is expected to be completed in the first half of 2025.

Summary of Significant Accounting Policies - Summary of Changes in Accumulated Other Comprehensive Loss by Component (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 430,671
Other comprehensive gain	(9,419)
Ending balance	410,338
Accumulated Other Comprehensive Loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(14,941)
Ending balance	(24,360)
Foreign Currency
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(14,941)
Other comprehensive gain	(9,419)
Ending balance	$ (24,360)

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
OPERATING ACTIVITIES:
Net (loss) income	$ (19,500)	$ 53,655	$ (17,133)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities
Stock-based compensation	11,920	10,729	11,622
Depreciation and amortization	10,872	20,936	15,308
Loss on impairments	4,392	10,829	17,101
Other non-cash amortization	(564)	3	228
Provision for credit losses	71	(462)	(1,032)
Unrealized foreign currency (gain) loss	(263)	103	(161)
Interest expense on finance leases	22	51	94
Loss on equity investment	1,700	0	0
Deferred income taxes	(657)	102	(1,651)
Loss on sale of fixed assets	563	0	729
Change in the estimated fair value of acquisition-related contingent consideration	0	(99)	(188)
Payment of acquisition-related contingent consideration	0	(19)	0
Changes in assets and liabilities:
Accounts receivable	15,872	31,116	(25,162)
Inventories	13,096	48,228	(43,274)
Prepaid expenses and other assets	4,089	(2,499)	(7,091)
Accounts payable	(7,577)	(26,976)	2,634
Deferred revenue	(219)	(730)	(596)
Accrued expenses and other liabilities	(6,443)	(3,384)	1,370
Net cash provided by (used in) operating activities	27,374	141,583	(47,202)
INVESTING ACTIVITIES:
Purchases of short-term investments	(53,244)	(74,652)	(22,873)
Purchase of equity method investee	(30,000)	0	0
Proceeds from maturities and redemptions of short-term investments	53,052	102,440	47,415
Acquisition of business, net of cash acquired	(5,037)	0	0
Proceeds from sale of assets	0	0	121
Purchases of property and equipment	(3,797)	(5,802)	(6,774)
Purchase of property and equipment under government contracts	0	(4,501)	(57,135)
Proceeds from funding under government contract	0	48,669	60,331
Net cash (used in) provided by investing activities	(39,026)	66,154	21,085
FINANCING ACTIVITIES:
Cash payments for lease liabilities	(842)	(1,345)	(1,381)
Proceeds from exercise of stock options	214	269	15
Payment of acquisition-related contingent consideration	0	(46)	(208)
Repurchase of common stock	(3,548)	(1,901)	(2,254)
Net cash used in financing activities	(4,176)	(3,023)	(3,828)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(6,816)	1,713	(2,837)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(22,644)	206,427	(32,782)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	290,407	83,980	116,762
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 267,763	$ 290,407	$ 83,980

Inventories (Tables)

12 Months Ended

Dec. 31, 2024

Inventory Disclosure [Abstract]

Schedule of Inventories


	December 31,
	2024		2023
Raw materials	$	17,001	$	20,727
Work in process	420		1,900
Finished goods	16,775		24,987
	$	34,197	$	47,614

Retirement Plans	12 Months Ended
Retirement Plans	Dec. 31, 2024
Retirement Benefits [Abstract]
Retirement Plans	RETIREMENT PLANS: Substantially all of the Company's U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for the Company to match employee contributions up to $4.0 thousand per year. The Company contributed $1.2 million, $1.6 million and $1.8 million to the 401(k) Plan, net of forfeitures, in 2024, 2023, and 2022, respectively. In addition to the Company's 401(k) plan, the Company offers a nonqualified deferred compensation plan to permit eligible directors and highly compensated employees of the Company to defer receipt and taxation of their compensation each year. The Company also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2024 and 2023, the value of the assets associated with this plan was $0.7 million and $0.8 million, respectively, and is included in other current assets and other noncurrent assets in the Company's consolidated balance sheets. The Company's obligation related to the deferred compensation plan is included in accrued expenses and other noncurrent liabilities in the Company's consolidated balance sheets. As of December 31, 2024 and 2023, the Company's total obligation under this plan was $0.7 million and $0.8 million, respectively. Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Canada Revenue Agency. The RRSP also provides for DNAG to match employee contributions up to $4.0 thousand CAD per year. The Company contributed $0.4 million, $0.4 million and $0.5 million to the RRSP in 2024, 2023, and 2022, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

+ Details

The Company - Additional Information (Detail) - segment	11 Months Ended	12 Months Ended
The Company - Additional Information (Detail) - segment	Dec. 31, 2023	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	2	1
Number of reportable segments		1

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Contingency [Line Items]
Foreign income tax expense (benefit)		$ 1,400	$ 700	$ 500
State income tax expense (benefit)		100	1,900	1,000
U.S. federal income tax benefits		229	0	0
Operating loss carryforwards		37,858
Foreign earnings repatriated	$ 65,000
Gross unrecognized tax benefits		333	304	373	$ 805
Domestic Tax Jurisdiction
Income Tax Contingency [Line Items]
Operating loss carryforwards		108,600
Operating loss carryforwards, acquired		71,500
Foreign Tax Jurisdiction
Income Tax Contingency [Line Items]
Operating loss carryforwards		63,000
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Operating loss carryforwards		33,900
Operating loss carryforwards, acquired		$ 4,000
Canada
Income Tax Contingency [Line Items]
Foreign income tax expense (benefit)			$ (1,200)
Withholding tax paid on the repatriation				$ 1,700

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2024	Feb. 24, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Entity File Number	001-16537
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Trading Symbol	OSUR
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 314,835,036
Entity Common Stock, Shares Outstanding		74,800,131
Documents Incorporated by Reference	Part III of this Annual Report on Form 10-K will be incorporated by reference from certain portions of the Registrant's Definitive Proxy Statement for its 2025 Annual Meeting of Shareholders, or will be included in an amendment hereto, to be filed not later than 120 days after the close of the fiscal year ended December 31, 2024. Except with respect to information specifically incorporated by reference in the Annual Report on Form 10-K, the Definitive Proxy Statement is not deemed to be filed as part hereof.
Amendment Flag	false
Entity Central Index Key	0001116463
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Finance Lease Liabilities, Payments, Due [Abstract]
2025	$ 48
2026	48
2027	42
2028	25
2029	6
Thereafter	0
Total minimum lease payments	169
Less: imputed interest	(15)
Present value of lease liabilities	154
Operating Lease Liabilities, Payments Due [Abstract]
2025	2,559
2026	2,373
2027	2,141
2028	2,081
2029	2,020
Thereafter	5,722
Total minimum lease payments	16,896
Less: imputed interest	(2,446)
Present value of lease liabilities	$ 14,450

Inventories

12 Months Ended

Dec. 31, 2024

Inventory Disclosure [Abstract]

Inventories

INVENTORIES:


	December 31,
	2024		2023
Raw materials	$	17,001	$	20,727
Work in process	420		1,900
Finished goods	16,775		24,987
	$	34,197	$	47,614

During the years ended December 31, 2024, 2023, and 2022, the Company recorded adjustments to inventory which had a cost of $2.6 million, $8.9 million, and $15.6 million, respectively. Adjustments for the year ended December 31, 2024 were primarily driven by the write down of inventory based on an estimated amount of inventory that may not be sold as the Company exits the Risk Assessment Testing business and normal operating scrap. Adjustments for the year ended December 31, 2023 were primarily related to reduction in COVID-19 demand and the need to reserve for excess inventory levels. Additionally, a significant portion of the Company's 2022 adjustments were related to production and tech-transfer issues associated with the Company's COVID-19 rapid test.

Stockholders' Equity - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants under the Stock Plan	5,412,000
Award requisite service period	3 years
Achievement period	3 years
Total compensation cost	$ 11,920,000	$ 10,729,000	$ 11,622,000
Proceeds from exercise of stock options	214,000	269,000	15,000
Income tax benefit realized from stock option exercises during period	0	0	0
Total cost of common stock purchased and retired	$ 3,548,000	$ 1,901,000	$ 2,254,000
Amount share repurchase program of common shares				$ 25,000,000
Share Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	0	0
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price	75.00%
Granted exercise period	10 years
Vesting period	4 years
Weighted-average grant date fair value of stock options granted (in US dollars per share)	$ 3.68	$ 3.24	$ 4.15
Total compensation cost	$ 1,400,000	$ 1,300,000	$ 1,500,000
Aggregate intrinsic value of options exercised	38,400	43,000.0	4,000.0
Unrecognized compensation expense related to unvested option awards	$ 2,600,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	2 years 7 months 6 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 6,900,000	$ 7,600,000	$ 9,200,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 8 months 12 days
Unrecognized compensation expense related to unvested restricted stock awards	$ 6,000,000.0
Vesting of restricted shares, withholding and exercise obligations	617,000	262,000	241,000
Restricted shares of common stock, aggregate values	$ 3,400,000	$ 1,400,000	$ 1,600,000
Performance Based Restricted Stock \| Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock \| Share-based Compensation Award, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 3,600,000	$ 1,800,000	$ 900,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 8 months 12 days
Unrecognized compensation expense related to unvested restricted stock awards	$ 5,300,000
Number of shares purchased and retired	23,000	86,000	88,000
Total cost of common stock purchased and retired	$ 200,000	$ 500,000	$ 600,000
Maximum \| Performance Based Restricted Stock \| Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of actual performance share units granted	150.00%
Minimum \| Performance Based Restricted Stock \| Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of actual performance share units granted	0.00%

Government Capital Contracts - Summary of Government Contracts Included in Statements of Cash Flows (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of assets, cumulative	$ 111,023	$ 130,563
Total property, plant and equipment, net	$ 45,105	45,420
Government Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of assets, cumulative		86,993
Reduction for funding earned to date, not yet received		0
Reduction for funding received to date		(86,993)
Total property, plant and equipment, net		$ 0

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Beginning balance	$ 35,696
Ending balance	40,330	$ 35,696
Collection Device
Goodwill [Roll Forward]
Beginning balance	35,696	35,104
Change related to foreign currency translation	(1,754)	592
Ending balance	33,942	35,696
Diagnostics
Goodwill [Roll Forward]
Beginning balance	0	0
Acquisition	6,388	0
Ending balance	$ 6,388	$ 0

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2024
Audit Information [Abstract]
Auditor Name	GRANT THORNTON LLP
Auditor Location	Philadelphia, PA
Auditor Firm ID	248

Stockholders' Equity - Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan (Detail) - Restricted Stock Award and Restricted Stock Units shares in Thousands	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares) \| shares	2,521
Granted (in shares) \| shares	875
Vested (in shares) \| shares	(1,604)
Forfeited (in shares) \| shares	(98)
Ending balance (in shares) \| shares	1,694
Issued and expected to vest (in shares) \| shares	1,694
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Beginning balance (in US dollars per share) \| $ / shares	$ 6.04
Granted (in US dollars per share) \| $ / shares	6.84
Vested (in US dollars per share) \| $ / shares	5.81
Forfeited (in US dollars per share) \| $ / shares	7.37
Ending balance (in US dollars per share) \| $ / shares	6.60
Issued and expected to vest (in US dollars per share) \| $ / shares	$ 6.60

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net loss	$ (19,500)	$ 53,655	$ (17,133)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Termination Benefits

12 Months Ended

Dec. 31, 2024

Termination Benefits [Abstract]

Termination Benefits

TERMINATION BENEFITS:

2023 Reduction in Workforce

During the first and second quarters of 2023, the Company executed a reduction in workforce. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):


	For the Year Ended December 31,
	2023
Cost of products and services sold	$	369
Research and development	566
Sales and marketing	1,543
General and administrative	787
	$	3,265

As of December 31, 2024 the Company had fully paid the $3.3 million related to the reduction in workforce. No additional expense associated with the 2023 reduction in workforce was incurred during the year ended December 31, 2024. This reduction in workforce was completed by June 30, 2024.

Q1 2024 Reduction in Workforce

During the first quarter of 2024, the Company executed a reduction in workforce largely affecting its COVID-19 manufacturing workforce. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statement of operations are as follows (in thousands):


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	231
Research and development	87
Sales and marketing	69
General and administrative	17
	$	404

As of December 31, 2024, the Company had fully paid the $0.4 million related to the reduction in workforce. This reduction in workforce was completed by December 31, 2024.

Q2 2024 Reduction in Workforce

During the second quarter of 2024, the Company executed an additional reduction in workforce as the Company notified employees of its intention to consolidate its Novosanis site in Belgium into other locations by the end of December 31, 2024, discontinue the Diversigen molecular services line of business by the end of June 30, 2024, and consolidate facilities by bringing third-party manufacturing activities into its Pennsylvania facilities by the end of the third quarter of 2025. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	889
Research and development	478
Sales and marketing	125
General and administrative	160
	$	1,652

As of December 31, 2024 the Company had $0.5 million accrued and had paid $1.2 million related to the reduction in workforce. The Company expects this reduction in workforce to be completed by September 2025.

Q3 2024 Reduction in Workforce

During the third quarter of 2024, the Company executed a reduction in workforce largely as the Company notified certain employees of its intention to discontinue its risk assessment business. Additional employees were notified in the fourth quarter of 2024. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	246
Research and development	33
Sales and marketing	782
General and administrative	141
	$	1,202

As of December 31, 2024 the Company had $1.1 million accrued and had paid $0.1 million related to the reduction in workforce. The Company expects this reduction in workforce to be completed by January 2026.

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 774	$ 1,216
Preferred stock, par value (in US dollars per share)	$ 0.000001	$ 0.000001
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in US dollars per share)	$ 0.000001	$ 0.000001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	74,598,000	73,528,000
Common stock, shares outstanding (in shares)	74,598,000	73,528,000

Summary of Significant Accounting Policies - Schedule of Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Guaranteed investment certificates	$ 267,763	$ 290,407
Acquisition-related contingent consideration obligation	22,910	0
Level I Instruments
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Guaranteed investment certificates	$ 66,584	71,698
Level III Instruments
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Acquisition-related contingent consideration obligation		$ 0

Business Segment Information - Presentation of Total Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 58,692	$ 58,266
United States
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	40,286	48,311
United Kingdom
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	12,849	0
Canada
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	5,468	8,777
Other regions
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 89	$ 1,178

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2024

Share-Based Payment Arrangement [Abstract]

Weighted-Average Assumptions for Fair Value Measurement

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	For the Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2024		2023		2022
Risk-free interest rate (1)	4.14	%	4.23	%	1.65	%
Expected dividend yield	—		—		—
Expected stock price volatility (2)	53	%	51	%	50	%
Expected life of stock options (in years) (2)	5		5		5

(1)Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options.

(2)Based upon historical experience.

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity under the Stock Plan:


	Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding on January 1, 2024	2,070	$	9.27
Granted	595	6.99
Exercised	(32)	6.70
Expired	(188)	11.19
Forfeited	(208)	7.20
Outstanding on December 31, 2024	2,237	$	8.73	6.33	$	—
Vested or expected to vest as of December 31, 2024	2,198	$	8.72	6.44	$	—
Exercisable on December 31, 2024	1,389	$	9.79	4.91	$	—

Schedule of Currently Outstanding and Exercisable Stock Options

The following table summarizes information about stock options outstanding as of December 31, 2024:


Options Outstanding					Options Exercisable
Range of Exercise Prices	Number Outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price Per Share		Number Exercisable	Weighted- Average Exercise Price Per Share
$4.26 - $6.82	578	7.35	$	5.98	285	$	6.02
$7.13 - $10.69	1,277	6.51	7.89		728	8.21
$12.90 - $19.34	334	4.33	14.87		329	14.86
$21.64 - $32.46	48	2.78	$	21.65	47	$	21.65
	2,237	6.33	$	8.73	1,389	$	9.79

Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2024	2,521	$	6.04
Granted	875	6.84
Vested	(1,604)	5.81
Forfeited	(98)	7.37
Issued and unvested, December 31, 2024	1,694	$	6.60
Issued and expected to vest, December 31, 2024	1,694	$	6.60

Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan

The following table summarizes PSU activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2024	991	$	6.52
Granted (1)	519	8.87
Performance adjustment (2)	18	N/A
Vested	(74)	10.99
Forfeited	—	—
Issued and unvested, December 31, 2024	1,454	$	7.19
Issued and expected to vest, December 31, 2024	1,454	$	7.19

(1)Grant activity for all PSUs disclosed at target.

(2)Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Leases - Additional Information (Detail) $ in Millions	12 Months Ended
Leases - Additional Information (Detail) $ in Millions	Dec. 31, 2024 USD ($)
Lessee Lease Description [Line Items]
Lessee operating and financing leases, period of options to terminate	1 year
Operating lease, impairment loss	$ 1.2
Finance lease, impairment loss	$ 0.3
Minimum
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	1 year
Maximum
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	10 years

Commitments and Contingencies - Schedule of Estimate of Future Purchases (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2025	$ 1,443
2026	0
2027	0
2028	0
2029	0
Total	$ 1,443

Business Segment Information - Additional Information (Detail) - segment	11 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2024
Segment Reporting [Abstract]
Number of operating segments	2	1
Number of reportable segments		1

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Risk-free interest rate

^[1]

4.14%

4.23%

1.65%

Expected dividend yield

0.00%

Expected stock price volatility

^[2]

53.00%

51.00%

50.00%

Expected life of stock options (in years)

^[2]

5 years

[1]	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options.
[2]	Based upon historical experience.

Accrued Expenses And Other Current Liabilities

12 Months Ended

Dec. 31, 2024

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES:


	December 31,
	2024		2023
Payroll and related benefits	$	11,147	$	14,654
Professional fees	2,469		2,827
Sales tax payable	1,339		1,245
Other	5,224		3,984
	$	20,179	$	22,710

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (19,500)	$ 53,655	$ (17,133)
OTHER COMPREHENSIVE LOSS
Currency translation adjustments	(9,419)	3,274	(8,572)
Unrealized gain on marketable securities	0	220	214
COMPREHENSIVE (LOSS) INCOME	$ (28,919)	$ 57,149	$ (25,491)

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Leases - Summary of Lease Term and Discount Rate (Detail)	Dec. 31, 2024	Dec. 31, 2023
Weighted Average Remaining Lease Term
Weighted-average remaining lease term — operating leases	7 years 6 months 25 days	8 years 6 months 3 days
Weighted-average remaining lease term — finance leases	3 years 8 months 26 days	1 year 8 months 15 days
Weighted Average Discount Rate
Weighted-average discount rate — operating leases	4.44%	3.71%
Weighted-average discount rate — finance leases	4.82%	3.45%

Business Segment Information

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Business Segment Information

BUSINESS SEGMENT INFORMATION:

The Company is organized on the basis of products and services into a single reportable segment. All products and services reside under the same reporting hierarchy. Historically, there was separate management leading the Company's Diagnostics and Molecular Solutions businesses. In February 2023, the Company announced a corporate restructuring to combine the commercial and innovation teams across the Diagnostics and Molecular Solutions businesses into one operating segment with sales, marketing, product development and research teams covering all product lines and reporting to a Chief Product Officer ("CPO").

The Company's reportable segment derives its revenues from the sale of diagnostics products and sample management solutions, as described in Note 2 Summary of Significant Accounting Policies. As the Company has only one reportable segment, there are no inter-segment sales or transfers.

The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM uses consolidated net income (loss) as reported in the consolidated statement of operations as the primary measure of the reportable segment's profit or loss. The CODM uses consolidated net income (loss) to assess the performance of the segment and make decisions about resource allocation. Consolidated gross profit and consolidated operating income (loss), as reported in the consolidated statement of operations, are also used by the CODM as measures of segment profit or loss. The CODM uses gross profit to assess the impact of the Company's efforts to achieve manufacturing efficiencies and consolidate its production activities. The CODM uses operating income (loss) to assess the impact of the Company's recent restructurings, reduction in workforce, and efforts to streamline its operations to achieve cost savings. The CODM uses consolidated total assets as the measure of segment assets, as reported on the consolidated balance sheet.

The accounting policies of the Company's reportable segment are the same as those described in Note 2 Summary of Significant Accounting Policies.

The following table represents total long-lived assets by geographic area:


	December 31,
	2024		2023
United States	$	40,286	$	48,311
United Kingdom	12,849		—
Canada	5,468		8,777
Other regions	89		1,178
	$	58,692	$	58,266

The following table represents reported segment revenues, segment profit (loss), and significant segment expenses:


	For the Years Ended December 31,
	2024		2023		2022
Net revenues	$	185,827	$	405,472	387,479
Cost of products and services sold (3)	106,437		233,820		239,041
Gross profit	79,390		171,652		148,438
Research and development (3)	26,047		33,728		36,237
Sales and marketing (3)	30,986		36,319		49,238
General and administrative (3)	46,215		58,191		68,206
Loss on impairments	4,392		10,829		17,101
Change in the estimated fair value of acquisition-related contingent consideration	—		(99)		(188)
Operating (loss) income	(28,250)		32,684		(22,156)
Other (expense) income (1)	(380)		17,836		3,453
Interest revenue	11,469		5,862		1,569
Other segment items (2)	1,160		(124)		1,459
(Loss) income before income taxes	(16,001)		56,258		(15,675)
Income tax expense	1,799		2,603		1,458
Loss on equity investment	(1,700)		—		—
Net (loss) income	$	(19,500)	$	53,655	$	(17,133)

(1) Includes $12.8 million of excess profits recognized on government contracts in 2023.

(2) Includes interest expense and foreign currency gains (losses).

(3) The following tables represent additional significant segment expense categories:


	For the Years Ended December 31,
	2024		2023		2022
Stock-based Compensation
Cost of products and services sold	$	734	$	564	$	334
Research and development	839		1,159		1,128
Sales and marketing	1,129		1,181		1,702
General and administrative	9,219		7,826		8,458
	$	11,920	$	10,729	$	11,622


	For the Years Ended December 31,
	2024		2023		2022
Depreciation and Amortization
Cost of products and services sold	$	6,343	$	15,311	$	9,230
Research and development	1,029		1,208		1,098
Sales and marketing	189		571		630
General and administrative	3,311		3,846		4,350
	$	10,872	$	20,936	$	15,308

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Termination Benefits - Additional Information (Details) $ in Millions	Dec. 31, 2024 USD ($)
2023 Reduction in Workforce
Termination Benefits [Line Items]
Payment of reduction in workforce	$ 3.3
Q1 2024 Reduction in Workforce
Termination Benefits [Line Items]
Payment of reduction in workforce	0.4
Q2 2024 Reduction In Workforce
Termination Benefits [Line Items]
Payment of reduction in workforce	1.2
Accrued reduction in workforce	0.5
Q3 2024 Reduction In Workforce
Termination Benefits [Line Items]
Payment of reduction in workforce	0.1
Accrued reduction in workforce	$ 1.1

Government Capital Contracts - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Oct. 31, 2023	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Government capital contracts funding amount		$ 109,000			$ 109,000
Percentage withheld under government contracts subject to validation testing				15.00%
Net revenues	$ 185,827	405,472	$ 387,479
Revenue in excess of guaranteed profit		12,800
Other Income
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues	$ 185,827	405,472	387,479
Revenue in excess of guaranteed profit		12,800
Other Income \| Government Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues		2,800	2,200
Research and Development Expenses and Other Income \| Government Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reimbursement of engineering cost		$ 2,000	$ 1,400

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Payroll and related benefits	$ 11,147	$ 14,654
Professional fees	2,469	2,827
Sales tax payable	1,339	1,245
Other	5,224	3,984
Total	$ 20,179	$ 22,710

Summary of Significant Accounting Policies - Contraction Risk (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Net Consolidated Revenue \| Non Commercial Customer
Product Information [Line Items]
Percentage of concentration risk	24.00%	63.00%
Accounts Receivable \| Non Commercial Customer
Product Information [Line Items]
Percentage of concentration risk		40.00%
Accounts Receivable \| Commercial Customer
Product Information [Line Items]
Percentage of concentration risk	10.00%

Income Taxes - Schedule of Operating Loss Carryforward (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 37,858
2026 to 2040
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	14,122
2041 to 2046
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	13,442
Non Expiring
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 10,294

Business Combinations (Tables)

12 Months Ended

Dec. 31, 2024

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition

The initial aggregate purchase price of this transaction was funded with cash on had as shown below:


Milestone contingent consideration	$	15,910
Royalty based contingent consideration	7,000
Cash paid to Sherlock	5,000
Legal expenses	389
Insurance policy expense	50
Initial aggregate purchase price	$	28,349

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired


Other current assets	$	2,570
Property, plant, and equipment, net	9,244
Other noncurrent assets	462
Operating right-of-use assets	4,080
In-process research and development technology intangible asset	17,000
Goodwill	6,382
Total assets acquired	39,738
Liabilities Assumed
Accounts payable	2,449
Current liabilities	3,621
Deferred revenue	1,641
Operating lease liability	4,080
Total liabilities assumed	11,791
Net Assets Acquired	27,947
Estimated fair value of contingent consideration	(22,910)
Net Cash Paid (net of cash acquired of $402)	$	5,037

Business Acquisition, Pro Forma Information


	For the Years Ended December 31,
	2024		2023
Net revenues	$	188,126	$	406,381
Net income (loss)	$	(41,459)	$	7,992

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Statutory U.S. federal income tax rate	21.00%	21.00%	21.00%
Nondeductible executive compensation	(8.50%)	0.50%	(5.80%)
Impact of stock-based payment awards	(2.30%)	(0.30%)	(5.10%)
Tax effect of foreign items	(1.90%)	(0.40%)	(6.00%)
State income taxes, net of federal benefit	(9.10%)	2.00%	(0.80%)
U.S. and foreign tax credits	1.20%	1.30%	3.70%
Nondeductible expenses and other	(2.40%)	0.90%	8.70%
Nondeductible transaction costs	(2.10%)	0.00%	0.00%
NOL adjustment, foreign	(31.40%)	0.00%	0.00%
Non-controlling interests	2.20%	0.00%	0.00%
Change in valuation allowance, federal and state	(10.00%)	0.00%	0.00%
Change in valuation allowance, foreign	32.10%	(20.40%)	(25.00%)
Effective tax rate	(11.20%)	4.60%	(9.30%)

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Gross	$ 32,848	$ 34,854
Accumulated Amortization	(32,413)	(33,649)
Net	435	1,206
Gross	49,848
Net	17,435	$ 1,206
IPR&D Technology
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 17,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	5 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Gross	$ 10,858	$ 11,629
Accumulated Amortization	(10,858)	(11,629)
Net	$ 0	$ 0
Patents and product rights
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	5 years	5 years
Gross	$ 7,495	$ 7,673
Accumulated Amortization	(7,399)	(7,102)
Net	96	571
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross	10,169	10,926
Accumulated Amortization	(10,169)	(10,926)
Net	$ 0	$ 0
Developed technology \| Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	7 years	7 years
Developed technology \| Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross	$ 4,327	$ 4,626
Accumulated Amortization	(3,988)	(3,991)
Net	$ 339	$ 635
Trade names \| Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	5 years	5 years
Trade names \| Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years	15 years

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit
shares in Thousands

12 Months Ended

Dec. 31, 2024

$ / shares

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]

Beginning balance (in shares)

991

Granted (in shares)

519

^[1]

Performance adjustment (in shares)

^[2]

Vested (in shares)

(74)

Forfeited (in shares)

Ending balance (in shares)

1,454

Issued and expected to vest (in shares)

1,454

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

Beginning balance (in US dollars per share) | $ / shares

$ 6.52

Granted (in US dollars per share) | $ / shares

8.87

^[1]

Vested (in US dollars per share) | $ / shares

10.99

Forfeited (in US dollars per share) | $ / shares

Ending balance (in US dollars per share) | $ / shares

7.19

Issued and expected to vest (in US dollars per share) | $ / shares

$ 7.19

[1]	Grant activity for all PSUs disclosed at target.
[2]	Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Transition Costs - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Transition Costs [Line Items]
Severance accrual		$ 1,600
Stock-based compensation	$ 11,920	$ 10,729	$ 11,622
Transition costs
Transition Costs [Line Items]
Stock-based compensation	$ 1,500

Retirement Plans - Additional Information (Detail)	12 Months Ended
Retirement Plans - Additional Information (Detail)	Dec. 31, 2024 USD ($)	Dec. 31, 2024 CAD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributed to plan, net of forfeitures	1,200,000		$ 1,600,000	$ 1,800,000
Value of the assets associated with the plan	700,000		800,000
Total obligation under plan	700,000		800,000
RRSP \| DNA Genotek
Defined Benefit Plan Disclosure [Line Items]
Employee contributions		$ 4,000
Contributed to plan, net of forfeitures	$ 400,000		$ 400,000	$ 500,000

Business Segment Information - Schedule of Additional Significant Segment Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting, Revenue Reconciling Item [Line Items]
Share-based compensation	$ 11,920	$ 10,729	$ 11,622
Depreciation and amortization	10,872	20,936	15,308
Cost of Products and Services Sold
Segment Reporting, Revenue Reconciling Item [Line Items]
Share-based compensation	734	564	334
Depreciation and amortization	6,343	15,311	9,230
Research and development
Segment Reporting, Revenue Reconciling Item [Line Items]
Share-based compensation	839	1,159	1,128
Depreciation and amortization	1,029	1,208	1,098
Sales and marketing
Segment Reporting, Revenue Reconciling Item [Line Items]
Share-based compensation	1,129	1,181	1,702
Depreciation and amortization	189	571	630
General and administrative
Segment Reporting, Revenue Reconciling Item [Line Items]
Share-based compensation	9,219	7,826	8,458
Depreciation and amortization	$ 3,311	$ 3,846	$ 4,350

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 17,001	$ 20,727
Work in process	420	1,900
Finished goods	16,775	24,987
Total	$ 34,197	$ 47,614

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Loss on impairments	$ 4,392	$ 10,829	$ 17,101
Depreciation expense	9,800	$ 17,900	11,700
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]		Loss on impairments
Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Loss on impairments	1,800
Machinery and equipment
Property, Plant and Equipment [Line Items]
Loss on impairments	$ 1,100
Pre-tax asset impairment charge		$ 2,300
Cost, Depreciation		6,900
Equipment and Leasehold Improvements
Property, Plant and Equipment [Line Items]
Loss on impairments			$ 13,500
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Cost, Depreciation		$ 500

Summary of Significant Accounting Policies - Summary of Earnings by Geographic Region (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation Of Revenue [Line Items]
Net revenues	$ 185,827	$ 405,472	$ 387,479
United States
Disaggregation Of Revenue [Line Items]
Net revenues	139,161	361,660	350,206
Europe
Disaggregation Of Revenue [Line Items]
Net revenues	8,424	8,111	11,536
Africa
Disaggregation Of Revenue [Line Items]
Net revenues	32,745	29,254	18,152
Other regions
Disaggregation Of Revenue [Line Items]
Net revenues	$ 5,497	$ 6,447	$ 7,585

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

+ References

+ Details

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 55,583	$ 28,014
Inventories	2,344	2,654
Capitalized research and development costs	12,946	3,897
Accruals and reserves currently not deductible	2,754	3,324
Acquired intangible assets	(3,981)	(164)
Depreciation and amortization	(2,017)	(3,567)
Right-of-use assets	(2,266)	(3,010)
Lease liabilities	2,497	3,173
Stock-based compensation	3,303	3,467
Tax credit carryforwards	4,184	3,326
Net deferred tax asset	75,347	41,114
Valuation allowance	(75,191)	(41,668)
Net deferred tax asset (liability)	$ 156
Net deferred tax asset (liability)		$ (554)

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Disaggregation of Revenue by Product and Geographic Area

The following table represents total net revenues by product line:


	For the Years Ended December 31,
	2024		2023		2022
HIV	$	60,804	$	60,823	$	38,812
Sample Management Solutions (1)	51,046		54,274		63,342
COVID-19 (2)	45,172		257,779		243,325
HCV	14,024		12,871		13,369
Risk Assessment Testing (3)	8,354		9,736		10,269
Other product and services revenues (4)	3,506		2,265		1,634
Molecular Services	1,705		4,474		7,296
Net product and services revenues	184,611		402,222		378,047
Non-product and services revenues (5)	1,216		3,250		9,432
Net revenues	$	185,827	$	405,472	$	387,479

(1) Includes Genomics, Microbiome and Colli-Pee product revenues.

(2) Includes COVID-19 Diagnostics and COVID-19 Molecular Products revenues.

(3) Includes substance abuse testing product revenues.

(4) Includes Syphilis revenues.

(5) Includes funded research and development contracts, royalty income and grant revenues.

The following table represents total net revenues by geographic area, based on the location of the customer:


	For the Years Ended December 31,
	2024		2023		2022
United States	$	139,161	$	361,660	$	350,206
Africa	32,745		29,254		18,152
Europe	8,424		8,111		11,536
Other regions	5,497		6,447		7,585
	$	185,827	$	405,472	$	387,479

Schedules of Concentration of Risk, by Risk Factor

The following table represents customer concentration risk:


	For the Years Ended December 31,
	2024	2023
Revenue Concentration

Non-commercial customer (1)	24%	63%

	December 31,
Accounts Receivable	2024	2023
Commercial customer	10%	N/A
Non-commercial customer (1)	N/A	40%

(1) Same non-commercial customer.

Schedule of Earnings Per Share, Basic and Diluted

Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.


	For the Years Ended December 31,
	2024		2023		2022
Net income (loss)	$	(19,500)	$	53,655	$	(17,133)
Weighted average shares of common stock outstanding:
Basic	74,434		73,348		72,505
Dilutive effect of stock options, restricted stock, and performance stock units	—		1,041		—
Diluted	74,434		74,389		72,505
Earnings per share:
Basic	$	(0.26)	$	0.73	$	(0.24)
Diluted	$	(0.26)	$	0.72	$	(0.24)

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in accumulated other comprehensive loss by component is listed below:


	Foreign Currency		Total
Balance at December 31, 2023	$	(14,941)	$	(14,941)
Other comprehensive loss	(9,419)		(9,419)
Balance at December 31, 2024	$	(24,360)	$	(24,360)

Schedule of Fair Value, Assets and Liabilities


		December 31,
	Level	2024		2023
Guaranteed investment certificates	1	$	66,584	$	71,698
Contingent consideration	3	$	22,910	$	—

Schedule of Accounts Receivable


	December 31,
	2024		2023		2022
Accounts receivable	$	23,816	$	40,171	$	70,797
Allowance for doubtful accounts	$	774	$	1,216	$	2,365

Schedule of Deferred Revenue


	December 31,
	2024		2023		2022
Deferred revenue	$	2,961	$	1,559	$	2,273

Goodwill and Other Intangible Assets - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) unit	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Goodwill [Line Items]
Number of reporting units \| unit	2
Amortization expense	$ 700	$ 2,000	$ 2,300
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]		Loss on impairments
Diagnostics
Goodwill [Line Items]
Pre-tax impairment charge			$ 3,600
Developed Technology, Trade Names And Customer Relationships
Goodwill [Line Items]
Impairment of intangible assets (excluding goodwill)		$ 6,200
Developed technology
Goodwill [Line Items]
Impairment of intangible assets (excluding goodwill)		$ 2,400

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021		72,069
Beginning balance at Dec. 31, 2021	$ 380,533	$ 0	$ 511,063	$ (10,077)	$ (120,453)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of options (in shares)		2
Common stock issued upon exercise of options	15		15
Vesting of restricted stock and performance stock units (in shares)		992
Purchase and retirement of common shares (in shares)		(329)
Purchase and retirement of common shares	(2,254)		(2,254)
Stock-based compensation	11,622		11,622
Net loss	(17,133)				(17,133)
Currency translation adjustments	(8,572)			(8,572)
Unrealized gain on marketable securities	214			214
Ending balance (in shares) at Dec. 31, 2022		72,734
Ending balance at Dec. 31, 2022	364,425	$ 0	520,446	(18,435)	(137,586)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of options (in shares)		44
Common stock issued upon exercise of options	269		269
Vesting of restricted stock and performance stock units (in shares)		1,098
Purchase and retirement of common shares (in shares)		(348)
Purchase and retirement of common shares	(1,901)		(1,901)
Stock-based compensation	10,729		10,729
Net loss	53,655				53,655
Currency translation adjustments	3,274			3,274
Unrealized gain on marketable securities	220			220
Ending balance (in shares) at Dec. 31, 2023		73,528
Ending balance at Dec. 31, 2023	$ 430,671	$ 0	$ 529,543	(14,941)	(83,931)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of options (in shares)	32	32	214
Common stock issued upon exercise of options	$ 214
Vesting of restricted stock and performance stock units (in shares)		1,678
Purchase and retirement of common shares (in shares)		(640)
Purchase and retirement of common shares	(3,548)		$ (3,548)
Stock-based compensation	11,920		11,920
Net loss	(19,500)				(19,500)
Currency translation adjustments	(9,419)			(9,419)
Unrealized gain on marketable securities	0
Ending balance (in shares) at Dec. 31, 2024		74,598
Ending balance at Dec. 31, 2024	$ 410,338	$ 0	$ 538,129	$ (24,360)	$ (103,431)

Business Combinations - Schedule of Pro Forma Financial Information (Details) - Sherlock Biosciences - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Net revenues	$ 188,126,000	$ 406,381,000
Net income (loss)	$ (41,459,000)	$ 7,992,000

Summary of Significant Accounting Policies - Summary Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net income (loss)	$ (19,500)	$ 53,655	$ (17,133)
Weighted average shares of common stock outstanding:
Basic	74,434	73,348	72,505
Dilutive effect of stock options, restricted stock, and performance stock units	0	1,041	0
Diluted	74,434	74,389	72,505
Earnings per share:
Basic earnings per share (in US dollars per share)	$ (0.26)	$ 0.73	$ (0.24)
Diluted earnings per share (in US dollars per share)	$ (0.26)	$ 0.72	$ (0.24)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details